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WELCOME TO THE WORLD OF
TOMORROW: AN EXPLORATION OF CELLBASED MEATS AND HOW THE FDA AND
USDA MAY PROTECT INTELLECTUAL
PROPERTY RIGHTS
Sean Anthony Grafton*

As the accumulation of greenhouse gases continues to cause the Earth to
warm,1 as the population continues to grow at an exponential rate causing food
shortage concerns,2 and as pollution of the Earth’s waterways continues to cause
growing concerns of clean water shortages,3 scientists continue to find new ways
to address these issues. After years of stem cell research, scientists have started
to address these issues by creating lab-grown meats, also known as cell-based
meats.4
*

Sean Grafton is a recently barred Washington, D.C. attorney with a background in genetic
research. He currently works for the United States Court of Federal Claims as a law clerk.
During law school, Sean interned for the U.S. Environmental Protection Agency Office of
Enforcement and Compliance Assurance (“OECA”) where he helped lead a multidepartment investigation of a major water polluter. Previously, Sean has worked in genetic
labs at both the Ohio State University and the University of Michigan. Using his science
background, he hopes to continue his career in the biotechnology and drug legal space
where he can bring his expertise in both fields together to effect positive change. He
graduated cum laude from the Catholic University of America, Columbus School of Law in
2019 and from Bowling Green State University in 2010.
1
Climate Change: How Do We Know?, NASA, https://climate.nasa.gov/evidence/ (last
visited Apr. 10, 2020).
2
Joseph Hincks, The World Is Headed for a Food Security Crisis. Here’s How We Can
Avert It, TIME (Mar. 28, 2018), http://time.com/5216532/global-food-security-richarddeverell/.
3
Stephen Leahy, From Not Enough to Too Much, the World’s Water Crisis Explained,
NAT’L GEOGRAPHIC (Mar. 22, 2018), https://news.nationalgeographic.com/2018/03/worldwater-day-water-crisis-explained/.
4
Mark J. Post, An Alternative Animal Protein Source: Cultured Beef, ANNALS N.Y.
ACAD. SCI., Nov. 2014, at 29, 30.
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Cell-based meats are meats grown using muscle tissues and stem cells in
laboratory conditions.5 Eventually, those stem cells grow into muscle fibers that
resemble and taste like the meats they are derived from.6 It is generally accepted
that these types of meats are called cell-based meats, but they also go by names
such as clean meat, artificial meat, cultured meat, or cultured tissue.7
Despite sounding like science fiction, the idea of growing meat in a laboratory
setting has held a special place in the public imagination. In 1931, Winston
Churchill wrote, “We shall escape the absurdity of growing a whole chicken in
order to eat the breast or wing, by growing these parts separately under a suitable
medium.”8 Cultivation of muscle tissue was shown to be successful as early as
1971 by Russell Ross.9 Ross reported that, “Smooth muscle derived from the
inner media and intima of immature guinea pig aorta were grown for up to 8
weeks in cell culture[s].”10
Cell-based meats are soon coming to grocery stores all around the country. 11
As cell-based meats get closer to coming to market, there will be serious
questions raised as to how to protect intellectual property (“IP”) rights related to
cell lines,12 how to protect IP rights related to growth processes,13 and which
government agency will regulate this area of the market.14
Part I of this Comment will discuss the general background of stem cells and
5
G. Owen Schaefer, Lab-Grown Meat, SCI. AM. (Sept. 14, 2018),
https://www.scientificamerican.com/article/lab-grown-meat/.
6
Id.
7
Sarah Zhang, The Farcical Battle over What to Call Lab-Grown Meat, THE ATLANTIC
(July 13, 2018), https://www.theatlantic.com/science/archive/2018/07/lab-grownmeat/565049/; Jamie Mah, Plant and Cell Based Meat, Explained, MEDIUM (Feb. 7, 2019),
https://medium.com/track-and-food/plant-and-cell-based-meat-explained-6c09dedad041.
8
Paul Shapiro, Commentary: Science Fiction No More, Can Lab-Grown Meat Feed—
and Save—the World?, REUTERS (Feb. 26, 2018), https://www.reuters.com/article/usshapiro-meat-commentary/commentary-science-fiction-no-more-can-lab-grown-meat-feedand-save-the-world-idUSKCN1GA25H.
9
See generally Russell Ross, The Smooth Muscle Cell: II. Growth of Smooth Muscle in
Culture and Formation of Elastic Fibers, 50 J. CELL BIOLOGY 172, 172 (1971).
10 Id.
11 Jade Scipioni, Lab-Grown Meat Coming to Supermarket Shelves Soon?, FOX BUS.
(May 1, 2017), https://www.foxbusiness.com/features/lab-grown-meat-coming-tosupermarket-shelves-soon.
12 Josephine Johnston, Intellectual Property and Biomedicine, HASTINGS CTR.,
https://www.thehastingscenter.org/briefingbook/intellectual-property-and-biomedicine/ (last
visited Apr. 10, 2020).
13 Chandra Nath Saha & Sanjib Bhattacharya, Intellectual Property Rights: An
Overview and Implications in Pharmaceutical Industry, 2 J. ADVANCED PHARMACEUTICAL
TECH. & RES. 88, 89 (2011).
14 Kelsey Piper, The Lab-Grown Meat Industry Just Got the Regulatory Oversight It’s
Been Begging For, VOX (Mar. 9, 2019, 8:00 AM), https://www.vox.com/futureperfect/2019/3/9/18255806/fda-usda-lab-grown-meat-cell-based-vegan-vegetarian.
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how cell-based meats are grown. Next, Part II will discuss the implications of
lab-grown meats in the world, including environmental impacts, social impacts,
and the effects on animal-rights movements. Part III will discuss how some of
the states that rely on traditional agriculture have responded to cell-based meats
coming to market. Then, Part IV will continue with an explanation of the prior
law of IP rights, cell rights, and expected Food and Drug Administration
(“FDA”) and United States Department of Agriculture (“USDA”) joint
regulation of cell-based meats. This part will also include a primer on the HatchWaxman laws. Part V will discuss some of the loopholes created by the HatchWaxman Act that will need to be addressed if new legislation is enacted to deal
with cell-based meats. Part VI will compare the FDA and USDA laws and
explain how the growing processes of lab-grown meats may find IP protections
the same way generic drugs have found protections through Hatch-Waxman.
Finally, Part VII will summarize the arguments: the FDA should be given full
regulatory authority in order to avoid undue delays in the patent process.
This Comment explores how cell-based meats will be regulated by the FDA
and the USDA, the current IP protections over the cells and growing processes,
and how Congress can provide IP protections over the individual cell lines and
the growing processes based on current IP frameworks in the generic drug world.
The main focus of this Comment will be how Congress could use the HatchWaxman Act15 as a framework to create new IP protections for cell-based meats
to give some additional IP protections to the companies producing cell-based
meats. The FDA16 will share regulatory responsibility with the USDA based on
initial conversations between the White House, FDA, and the USDA.17
Specifically, the FDA will regulate the food safety side of the industry.18 The
advantage of having the FDA involved in the regulation of cell-based meats is
that the FDA already has a history of providing additional IP protections for
drugs through the Hatch-Waxman Act.19 Thus, Congress should consider

See 21 U.S.C. § 355 (2012).
USDA and FDA Announce a Formal Agreement to Regulate Cell-Cultured Food
Products from Cell Lines of Livestock and Poultry, U.S. FOOD & DRUG ADMIN. (Mar. 7,
2019), https://www.fda.gov/news-events/press-announcements/usda-and-fda-announceformal-agreement-regulate-cell-cultured-food-products-cell-lines-livestock-and.
17 Wyatt Bechtel, Joint Letter Sent to President Trump on Lab-Grown Meat
Regulations, DROVERS (Aug. 23, 2018), https://www.drovers.com/article/joint-letter-sentpresident-trump-lab-grown-meat-regulations.
18 Formal Agreement Between FDA and USDA Regarding Oversight of Human Food
Produced Using Animal Cell Technology Derived from Cell Lines of USDA-Amenable
Species, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/food/domestic-interagencyagreements-food/formal-agreement-between-fda-and-usda-regarding-oversight-humanfood-produced-using-animal-cell (last updated Mar. 7, 2019) [hereinafter Formal
Agreement].
19 See 21 U.S.C. § 355 (2012).
15
16
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passing an act similar to Hatch-Waxman in the cell-based meat arena to help
implement IP protections over the cell-based meat growing processes as
companies wait for approval from the FDA and the USDA. Similar to drug
companies jumping into the generic drugs market after a successful showing of
the brand drug, there will be an increasing number of companies trying to enter
the cell-based meat market.20 Congress will need to address the issues of
competition and IP rights before it creates a backlog in the courts,21 or a few
companies create monopolies.22 The framework of the Hatch-Waxman Act
provides a practical example of how to do this moving forward.
I. BACKGROUND OF STEM CELLS AND CELL-BASED MEATS
A. The Science of Stem Cells
The science of stem cells has been studied and understood for a long time.23
Stem cells are pervasive in all living things and among all types of cells and
tissues.24 In the simplest sense, stem cells are the cells that have yet to
differentiate into specific cells or tissues.25 These cells are influenced by the
surrounding cells and have demonstrated the surprising ability to transform into
other tissues and cell types.26 Eventually, these stem cells can become muscle
tissue, skin, or red blood cells.27 Stem cells are the building blocks of the human
body and how the body renews itself.28
There are a few different types of stem cells including embryonic,29
20 Jessi Devenyns, Cell-Based Food Maker New Age Meats Raises $2.7M in Funding,
FOOD DIVE (Jan. 13, 2020), https://www.fooddive.com/news/cell-based-food-maker-newage-meats-raises-27m-in-funding/570267/.
21 Lawrence Hurley, U.S. High Court Sets Record for Intellectual Property Caseload,
REUTERS (Feb. 27, 2014), https://www.reuters.com/article/us-usa-court-ip-analysis/u-s-highcourt-sets-record-for-intellectual-property-caseload-idUSBREA1Q09B20140227.
22 Cultured Meat Market Leveraging the Environment Ramifications of Animal
Agriculture, INDUSTRYARC (Aug. 26, 2019),
https://www.industryarc.com/PressRelease/1749/Cultured-Meat-Market-Research.html.
23 The Adult Stem Cell, NAT’L INSTS. OF HEALTH, https://stemcells.nih.gov/info/
2001report/chapter4.htm (last visited Apr. 10, 2020).
24 Stem Cell Basics IV, NAT’L INSTS. OF HEALTH, https://stemcells.nih.gov/info/
basics/4.htm (last visited Apr. 10, 2020).
25 Stem Cell Basics I, NAT’L INSTS. OF HEALTH, https://stemcells.nih.gov/info/
basics/1.htm (last visited Apr. 10, 2020).
26 David A. Prentice, Adult Stem Cells, 19 ISSUES L. & MED. 265, 265 (2004).
27 Stem Cell Basics I, supra note 25.
28 Stem Cell Basics II, NAT’L INSTS. OF HEALTH, https://stemcells.nih.gov/info/
basics/1.htm (last visited Apr. 10, 2020).
29 Stem Cell Basics III, NAT’L INSTS. OF HEALTH, https://stemcells.nih.gov/info/
basics/1.htm (last visited Apr. 10, 2020).
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pluripotent, chord,30 and hematopoietic stem cells;31 however, the stem cells
used in growing cell-based meats are the specific animal’s adult stem cells.32
Adult stem cells have certain special characteristics, such as the ability to
duplicate themselves for long periods of time, which is referred to as long-term
self-renewal.33 These particular stem cells give rise to mature cell types that have
specialized functions after the cell duplicates and divides.34 The primary
functions of adult stem cells are to maintain the job of a cell and to replace dead
cells.35
When creating cell-based meats in a laboratory, scientists take certain animal
cells and place those cells in a blood-like growth medium with cells similar to
their future self; after some time, the result is a product that both tastes like and
functions the same as the meat it was harvested from.36 This is possible because
the adult stem cells only know how to replicate the specific cells which they are
programmed to become, regardless of whether they are in a living body or in a
Petri dish in a lab.37 Scientists will do this for both the smooth muscle meat cells
and the fat cells of an animal to create essentially the same product available
every day in grocery stores.38
B. Background of Cell-Based Meats
Lab-grown meats are made through a process called “cellular agriculture.”39
“Cellular agriculture is a method of agricultural production enabling the growth
of meat, eggs, and leather in cell culture rather than raising and slaughtering
livestock.”40 Researchers discovered this process after experimenting with
animal stem cells.41
Id.
Stem Cell Basics II, supra note 28.
32 Walter Johnson et al., Burgers Grown in a Lab Are Heading to Your Plate. Will You
Bite?, WASH. POST (Sept. 9, 2018), https://www.washingtonpost.com/national/healthscience/burgers-grown-in-a-lab-are-heading-to-your-plate-will-you-bite/2018/09/07/
1d048720-b060-11e8-a20b-5f4f84429666_story.html?utm_term=.a5e08e698a86.
33 The Adult Stem Cell, supra note 23.
34 Id.
35 Id.
36 Shaefer, supra note 5.
37 Stem Cell Basics II, supra note 28.
38 Yaakov Nahmias, Lab-Grown Meat Is Getting Cheap Enough for Anyone to Buy,
FAST COMPANY (May 2, 2018), https://www.fastcompany.com/40565582/lab-grown-meatis-getting-cheap-enough-for-anyone-to-buy.
39 Cell-Ag 101, CAS, https://www.cellag.org/cellag101/ (last visited Apr. 10, 2020).
40 Erin Kim, A Closer Look at Cellular Agriculture and the Processes Defining It,
AGFUNDER (July 5, 2016), https://agfundernews.com/closer-look-cellular-agriculture-andthe-processes-defining-it.html/.
41 Chase Purdy, The Idea for Lab-Grown Meat Was Born in a Prisoner-of-War Camp,
QUARTZ (Sept. 24, 2017), https://qz.com/1077183/the-idea-for-lab-grown-meat-was-born30
31
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One of the first reported cultivations of muscle fibers was in 1971 after
researchers grew guinea pig smooth heart muscle in Petri dishes.42 The United
States National Aeronautics and Space Administration (“NASA”) immediately
took an interest in cell-based meats so that its astronauts could have a source of
protein during prolonged space trips.43 In 2002, NASA funded a research project
focused on producing fish filets using cellular agriculture techniques.44 These
fish filets were breaded and fried before they were presented to a food panel.45
The panel commented that the cell-based fish sticks resembled and smelled like
real fish filets; however, FDA regulations prevented the panel from performing
a taste test because of health concerns.46
After the NASA experiment, the Dutch government funded research on
cultured meat from 2004 to 2009 and tasked Dr. Mark Post with leading the
project.47 Although the initial project did not result in a huge breakthrough, Dr.
Post continued his research independently after the Dutch government cut
funding. 48
In 2013, as a result of his research, Dr. Post was able to create and present the
first cell-based burger at a highly publicized conference in London.49 The cellbased burger was produced by “removing the stem cells from the shoulder
muscle of a cow, growing them into thin strips of muscle in tissue culture flasks,
and combining about 20,000 strips to make a burger.”50 Dr. Post displayed the
world’s first cultured beef hamburger that “served as a proof of concept for this
method, using established tissue engineering methods (the science of growing
organs for human medical use) to grow the cow muscle cells that formed the
beef patty.”51 As a result, “a small number of entrepreneurs are already

in-a-prisoner-of-war-camp/.
42 Ross, supra note 9, at 172.
43 Paul Shapiro, Lab-Grown Meat Is on the Way: It’s Good for the Planet, and Surveys
Show that Significant Numbers of People Would Be Willing to Give It a Try, SCI. AM. (Dec.
19, 2017), https://blogs.scientificamerican.com/observations/lab-grown-meat-is-on-theway/.
44 M.A. Benjaminson et al., In Vitro Edible Muscle Protein Production System (MPPS):
Stage 1, Fish, 51 ACTA ASTRONAUTICA 879 (2002).
45 Maddie Stone, Meet the Radical Scientists Who Want to Grow Our Seafood in a Lab,
GIZMODO (Feb. 9, 2016), https://gizmodo.com/meet-the-radical-scientists-who-want-togrow-our-seafoo-1752950596.
46 Laura Cassiday, Clean Meat, AOCS, https://www.aocs.org/stay-informed/readinform/featured-articles/clean-meat-february-2018 (last visited Apr. 10, 2020).
47 Id.
48 Id.
49 Id.
50 Id.
51 Kim, supra note 40.
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embracing the science and launching startups like Memphis Meats,52 Muufri,53
Clara Foods,54 Afineur,55 Meatable,56 and Gelzen.”57
Dr. Post’s research spawned several startups that show the promise of creating
a product that can be marketed.58 Meatable was created as a startup and has since
been backed by both the University of Cambridge and Stanford University. 59
The company has secured over $3.5 million in seed money from these
investors.60 Meatable has created cell lines of certain meats that will replicate
themselves indefinitely, creating a process that may tackle the scalability and
cost issues that accompany cell-based meats.61
Memphis Meats is another cell-based meat startup that has benefited greatly
from outside investing.62 Memphis Meats was founded in 2015 by a cardiologist
and a cellular scientist.63 The startup created its first lab-grown meatball a year
later and its first lab-grown poultry breast in March 2017.64 After its recent
success, Memphis Meats will try to bring its products to market by 2021.65
Memphis Meats has received substantial investments from both private and
public sources.66 It has received Class A investments from the likes of Bill Gates,

52

Home, MEMPHIS MEATS, https://www.memphismeats.com/ (last visited Apr. 16,

2020).
53 How It Works, PERFECT DAY FOODS, https://www.perfectdayfoods.com/ (last visited
Apr. 16, 2020).
54 Home, CLARA FOODS, https://www.clarafoods.com/ (last visited Apr. 16, 2020).
55 Home, AFINEUR, https://www.afineur.com/ (last visited Apr. 16, 2020).
56 Home, MEATABLE, https://www.meatable.com/ (last visited Apr. 16, 2020); see
Catherine Lamb, Meatable Claims to Hold the Key to Scalable Cultured Meat in a Single
Cell, SPOON (Oct. 5, 2018), https://thespoon.tech/meatable-claims-to-hold-the-key-toscalable-cultured-meat-in-a-single-cell/.
57 About Us, GELTOR, http://geltor.com/ (last visited Apr. 16, 2020); Kim, supra note
40.
58 Kim, supra note 40.
59 Jessica Hasson, Meatable to Feed the World with Breakthrough Single-Cell-Based
Meat Technology, GLOBE NEWSWIRE (Sept. 30, 2018), https://www.globenewswire.com/
news-release/2018/09/30/1587407/0/en/Meatable-to-Feed-the-World-with-BreakthroughSingle-Cell-based-Meat-Technology.html.
60 Id.
61 Id.
62 Memphis Meats Raises $161 Million for Cell-Based Meat, RED HERRING (Jan. 24,
2020), https://www.redherring.com/top-story/memphis-meats-raises-161-million-for-cellbased-meat/.
63 About, MEMPHIS MEATS, https://www.memphismeats.com/about (last visited Jan. 26,
2020).
64 Id.
65 Jon Card, Lab-Grown Food: “The Goal Is to Remove the Animal from Meat
Production”, GUARDIAN (July 24, 2017), https://www.theguardian.com/small-businessnetwork/2017/jul/24/lab-grown-food-indiebio-artificial-intelligence-walmart-vegetarian.
66 Elie Dolgin, Sizzling Interest in Lab-Grown Meat Belies Lack of Basic Research,
NATURE (Feb. 6, 2019), https://www.nature.com/articles/d41586-019-00373-w.
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Cargill, and Richard Branson.67 More recently, it received a very large
investment from Tyson.68 The company has raised over $17 million in series A
funding as of the end of 2017.69 These investors have been outspoken in their
support for lab-grown meats.70 Most of the support touted by these investors
stems from the hope that this new technology will help end world hunger, be
more environmentally friendly than current agricultural processes, and curve
adverse livestock treatment.71
II. IMPLICATIONS OF CELL-BASED MEATS FOR THE WORLD
There is a lot of excitement behind new cell-based meat technology. Much of
the excitement behind this technology is tied to the belief that it may solve the
world food crisis.72 This is because the labs that grow the meat do not require
much space to operate.73 Unlike farms that need space for animal grazing,
milking, and slaughtering, lab-grown meats only need the lab and an area for
harvesting.74 Thus, the physical footprint of agriculture can be reduced wherever
these labs are located. In addition, these labs can be placed in areas that do not
traditionally support livestock.75
Part of the world food crisis is influenced by the soaring prices, demand, and
supply of certain types of meats.76 Producing meat from livestock is extremely
inefficient.77 To produce one pound of beef, it requires more than “38 pounds of
feed and 1,799 gallons of water.”78 Farm animals are fed enough grain to end

67 Rick Morgan, Bill Gates and Richard Branson Are Betting Lab-Grown Meat Might
Be the Food of the Future, CNBC (Mar. 23, 2018), https://www.cnbc.com/2018/03/23/billgates-and-richard-branson-bet-on-lab-grown-meat-startup.html.
68 Id.
69 Emma Cosgrove, Memphis Meats Adds Tyson to Investor List with Cargill, Gates,
Branson, Musk, More, AGFUNDER (Jan. 29, 2018), https://agfundernews.com/memphismeats-raises-17m-series-cargill-gates-branson-musk.html/.
70 Gene Marks, Lab-Grown Meat of the Future Is Here—and May Even Sustainably Fill
Demand, GUARDIAN (Nov. 29, 2018), https://www.theguardian.com/business/2018/nov/29/
meat-poultry-sustainable-affordable-solution-lab-grown.
71 Morgan, supra note 67.
72 Jeff Bercovici, Why This Cardiologist Is Betting That His Lab-Grown Meat Startup
Can Solve the Global Food Crisis, INC. (Oct. 24, 2017), https://www.inc.com/magazine/
201711/jeff-bercovici/memphis-meats-lab-grown-meat-startup.html.
73 Marks, supra note 70.
74 Id.
75 Isha Datar, Environmental Impacts of Cultured Meat, NEW HARVEST (Nov. 19, 2015),
https://www.new-harvest.org/environmental_impacts_of_cultured_meat.
76 Karen McColl, Can We Feed the World?, 336 BMJ 1336, 1336–37 (2018).
77 Morgan, supra note 67.
78 Id.; Kai Olson-Sawyer, Meat’s Large Water Footprint: Why Raising Livestock and
Poultry for Meat Is So Resource-Intensive, FOOD TANK (Dec. 2013), https://foodtank.com/
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world hunger twenty times over.79
The total world population is forecasted to exceed nine billion people within
thirty years;80 humanity simply cannot sustain meat production for a population
of that size.81 In addition to food shortages, there will not be enough clean water
to support a population of that size, let alone agricultural and horticultural
needs.82 In light of the population, food, and water issues, proponents of cellculture meat are excited about the potential benefits because it is estimated that
this technology requires ”100 times less land and 5.5 times less water” than
traditional meat production.83
Once the technology is better perfected and becomes more efficient, the time
it takes to produce cell-based meats and to bring the product to table will be
greatly reduced. Currently, it takes between eighteen to twenty-four months to
bring a cow weighing over a thousand pounds to slaughter,84 and between eight
to twelve weeks for a chicken weighing slightly over five pounds.85 For cellbased meats, it is estimated that in ideal conditions this process can produce fifty
thousand tons of pork in just two months.86 Again, production time of cell-based
meats is likely to decrease, and yield is likely to increase once there are greater
technological advances and streamlined processes in this area.87
news/2013/12/why-meat-eats-resources/.
79 Morgan, supra note 67; Mimi Bekhechi, Five Things Would Happen if Everyone
Stopped Eating Meat, INDEP. (Jan. 31, 2016), https://www.independent.co.uk/voices/fivethings-would-happen-if-everyone-stopped-eating-meat-a6844811.html.
80 POPULATION DIV., UNITED NATIONS DEP’T OF ECON. & SOC. AFFAIRS, WORLD
POPULATION PROSPECTS: THE 2017 REVISION 1 (2017), https://population.un.org/wpp/
Publications/Files/WPP2017_KeyFindings.pdf.
81 Morgan, supra note 67; Nathan Halverson, The World Already Would Be Out of
Water if Everyone Ate Like Americans, REVEAL NEWS (Apr. 22, 2016),
https://www.revealnews.org/blog/the-world-wouldve-already-run-out-of-water-if-everyoneate-like-americans/.
82 Halverson, supra note 81.
83 Morgan, supra note 67; Our Meatless Future: How The $1.8T Global Meat Market
Gets Disrupted, CB INSIGHTS (Nov. 13, 2019), https://www.cbinsights.com/research/futureof-meat-industrial-farming/?utm_source=CB+Insights+Newsletter&utm_campaign=
999f46e7e8-FriNL_03_16_2018&utm_medium=email&utm_term=0_9dc0513989999f46e7e8-89466837.
84 Marybeth Feutz, Beef Cattle Life Stages, MY FEARLESS KITCHEN,
https://www.myfearlesskitchen.com/beef-cattle-life-stages/ (last visited Apr. 16, 2020)
(“[Cows fed with feedlot] are fed and taken care of until they reach around 1000–1200
pounds, which is usually around 18 months old.… Because [grass fed cows] don’t receive
the same amount of calories every day as their grain-fed counterparts, they are often closer
to three years old before they reach their finished weight.”).
85 Danelle Wolford, How to Raise Meat Chickens: Part 1, WEED’EM & REAP,
https://www.weedemandreap.com/raise-meat-chickens-part-1/ (last visited Apr. 16, 2020).
86 Damien Gayle, Artificial Meat Grown in a Lab Could Become a Reality This Year,
DAILY MAIL (Jan. 17, 2012), https://www.dailymail.co.uk/sciencetech/article-2087837/Testtube-meat-reality-year-scientists-work-make-profitable.html.
87 LIZ SPECHT & CHRISTIE LAGALLY, GOOD FOOD INST., MAPPING EMERGING
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Another rallying cry in support of cell-based meats is that they may reduce
environmental impacts.88 As climate change worsens, reducing greenhouse gas
emissions that contribute to the problem should be a priority for developed
nations because their intellectual, financial, and technological resources put
them in the best position to do so.89 The current estimate is that the world needs
to cut about 40 percent of global greenhouse gas emissions by 2050 to avoid a
global crisis.90
Livestock is a significant contributor to greenhouse gas emissions.91 Farming
livestock produces around 14.5 percent of global greenhouse gas emissions.92
The gases produced include carbon dioxide, methane, and nitrous oxide, and the
total production is around 7.1 gigatonnes of gases per year.93 Stem cells’
exponential multiplication means that the cells of only 150 cows could be needed
to feed the entire world; food manufacturers currently require 1.5 billion cows
to partially feed the world.94 However, cell-based meats will not solve the
climate change problem entirely. Still, cell-based meats cutting into the livestock
market can only help in the battle to reduce the effects of climate change, even
if it is only by a reduction in a few percentage points of emissions.95
Finally, animal rights activists are excited about this technology because it
INDUSTRIES: OPPORTUNITIES IN CLEAN MEAT 1–2 (2017), https://www.gfi.org/images/
uploads/2017/06/Mapping-Emerging-Industries.pdf.
88 Bahar Gholipour, Lab-Grown Meat May Save a Lot More than Farm Animals’ Lives,
NBC NEWS (Apr. 6, 2017), https://www.nbcnews.com/mach/innovation/lab-grown-meatmay-save-lot-more-farm-animals-lives-n743091.
89 Id.
90 Andrea Thompson, Major Greenhouse Gas Reductions Needed by 2050: IPCC,
CLIMATE CENTRAL (Apr. 13, 2014), http://www.climatecentral.org/news/major-greenhousegas-reductions-needed-to-curtail-climate-change-ipcc-17300.
91 Mario Herrero, To Reduce Greenhouse Gases from Cows and Sheep, We Need to
Look at the Big Picture, CONVERSATION (Mar. 21, 2016), http://theconversation.com/toreduce-greenhouse-gases-from-cows-and-sheep-we-need-to-look-at-the-big-picture-56509.
92 P.J. GERBER ET AL., FOOD & AGRIC. ORG. OF THE UNITED NATIONS, TACKLING
CLIMATE CHANGE THROUGH LIVESTOCK: A GLOBAL ASSESSMENT OF EMISSIONS AND
MITIGATION OPPORTUNITIES 15, 107 (2013) (explaining the updated report on greenhouse
gas emissions is generally consistent with the previous study indicating livestock emissions
contributed to 18 percent of greenhouse gas emissions, but the two figures cannot be
accurately compared given their different data inputs in calculating this amount); Herrero,
supra note 91.
93 GERBER ET AL., supra note 92, at 15; Herrero, supra note 91.
94 Post, supra note 4, at 29–30 (explaining the economic efficiency of cultured beef is
contingent upon reducing the production costs of developing it); Cassiday, supra note 46.
95 Hanna Tuomisto & M. Joost Teixeira de Mattos, Environmental Impacts of Cultured
Meat Production, 45 ENVTL. SCI. & TECH. 6117, 6117 (2011); AMY L. LUERS ET AL., UNION
OF CONCERNED SCIENTISTS, HOW TO AVOID DANGEROUS CLIMATE CHANGE: A TARGET FOR
U.S. EMISSIONS REDUCTIONS 2 (2007), https://www.ucsusa.org/resources/target-usemissions-reductions (“To meet this minimum target, the United States must reduce its
emissions an average of 4 percent per year starting in 2010.”).
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ensures that no actual animals are caged in close, unsanitary conditions or
abused in any manner.96 This should ease consumer concerns about animal
husbandry, thereby opening a whole new market of meat products to those who
did not previously eat meat due to abuse, raising conditions, or other ethical
concerns.97
However, opponents of this technology focus on how cell-based meats are
simply theoretical; thus, any hopes that a product can tackle some of the biggest
issues faced by modern humanity are purely conjectural.98 The cost of the meat
and the cost of energy to grow the meat would cancel out any environmental or
efficiency argument.99 In addition, cell-based meat arguments do not account for
the fact that the rest of the cow is used to create other products.100 The
byproducts made from the cow include leather, soaps, cosmetics, pet food,
fertilizer, vaccines, and prescription medicines.101
Even though other valid arguments related to uses of the animal carcass exist
against the current state of cell-based meat technology, this technology will only
continue to improve to increase the efficiency and lower the environmental
impact of the process.102 In addition, if the cell-based meat technology takes off
as its proponents claim, society can expect some market corrections to the
leather industry where there will still be enough cows raised for these purposes
and for meat, or other forms of synthetic leather created.103 Some companies are
innovating to produce these other byproducts with just the cells from animals
and without harvesting the animals.104 For example, Modern Meadow has
developed a process to use genetically engineered yeast to produce bovine
collagen.105 That collagen is then assembled into layers of leather that can be
worked like traditional leather.106

96 Cellular Agriculture: The Future of Food, CELL AGRI, https://www.cell.ag/cellularagriculture-future-of-food/ (last visited Apr. 13, 2020); PETA’s ‘In Vitro’ Chicken Contest,
PETA, https://www.peta.org/features/vitro-meat-contest/ (last visited Apr. 13, 2020).
97 See Cellular Agriculture: The Future of Food, supra note 96.
98 Suzanne Jacobs, Lab-Grown Meat Could Be the Future—If We Can Figure Out How
to Make It Not Gross, VOX (Aug. 15, 2015), https://www.vox.com/2015/8/15/9149725/
laboratory-meat.
99 Cassiday, supra note 46.
100 Id.
101 Id.; Daniel Marti et al., Beef and Pork Byproducts: Enhancing the U.S. Meat
Industry’s Bottom Line, USDA (Sept. 1, 2011), https://www.ers.usda.gov/amberwaves/2011/september/beef-and-pork-byproducts/.
102 See Cassiday, supra note 46.
103 Id.
104 Id.
105 Id.; Our Technology, MOD. MEADOW, http://www.modernmeadow.com/ourtechnology/ (last visited Apr. 13, 2020).
106 Cassiday, supra note 46; Our Technology, supra note 105.
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A. Food Safety
In addition to the environmental benefits, experts also believe that cell-based
meats could be safer than traditional meats.107 Salmonella and Escherichia
coli are always a concern when preparing traditional meats for consumption
because these bacteria exist in nearly all livestock meats and can be transferred
to humans if the meat is not cooked properly.108 When people ingest Salmonella
or E. coli, they can experience a wide range of symptoms from mild discomfort
to severe dehydration.109 This is also known as food poisoning.110
Not all strains of these bacteria cause illness.111 The human body has strains
of E. coli within its normal biome.112 Similarly, cattle and poultry also have
certain strains of these bacteria in their respective systems that are not
pathogenic to them.113 However, the E. coli found in their gastrointestinal track
is pathogenic to humans.114 These specific strains of E. coli can contaminate
food, like ground beef, during the food processing stage.115
It takes a few days for the bacteria to promulgate enough to cause harm to the
human body.116 This is when it is called food poisoning.117 If enough people get
sick, then the manufacturer may recall the product, which is a costly process.118
The USDA published figures showing that, in 2018, there were 31 beef recalls
amounting to 13,185,563 pounds of product lost and 34 poultry recalls
amounting to 1,214,839 pounds of product lost.119
Cassiday, supra note 46.
Id.; E. coli, MAYO CLINIC, https://www.mayoclinic.org/diseases-conditions/ecoli/symptoms-causes/syc-20372058 (last visited Apr. 13, 2020); Salmonella Infection,
MAYO CLINIC, https://www.mayoclinic.org/diseases-conditions/salmonella/symptomscauses/syc-20355329 (last visited Apr. 13, 2020).
109 Food Poisoning Symptoms, CDC, https://www.cdc.gov/foodsafety/symptoms.html
(last updated Oct. 11, 2019).
110 Brandon Baker, How to Avoid Food Poisoning from E. coli and Salmonella, PENN
TODAY (June 5, 2018), https://penntoday.upenn.edu/news/how-avoid-food-poisoning-e-coliand-salmonella.
111 Id.
112 Id.
113 Id.; What Foodborne Organisms Are Associated with Meat and Poultry?, AM. MEAT
SCI. ASS’N (Nov. 12, 2015), https://meatscience.org/TheMeatWeEat/topics/meatsafety/article/2015/11/12/what-foodborne-organisms-are-associated-with-meat-and-poultry.
114 Baker, supra note 110.
115 Id.; How Food Gets Contaminated—The Food Production Chain, CDC,
https://www.cdc.gov/foodsafety/production-chain.html (last updated Sept. 5, 2017).
116 Baker, supra note 110.
117 Id.
118 Id.; Jessica White-Carson, Understanding Food Recalls: The Recall Process
Explained, FOOD SAFETY NEWS (Aug. 12, 2013), https://www.foodsafetynews.com/2013/08/
understanding-food-recalls-the-recall-process-explained/.
119 Summary of Recall Cases in Calendar Year 2018, USDA FSIS,
107
108
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The introduction of pathogens into food will not be a problem for cell-based
meat products.120 Since cell-based meats are grown in sterile conditions,
scientists can test for and prevent contamination before the product goes to
market.121 The introduction of cell-based meats to market may reduce the
incidents of commercial pathogen or other emerging diseases, which are linked
to livestock farming.122 The ability to control exactly what is in the food product
throughout all stages of growth will save costs by avoiding the expensive recalls
and preventing illness.123
In addition, cell-based meats could help reduce the growing concern of
superbugs that has resulted from widespread antibiotics use in livestock.124
When an antibiotic is overused without killing off all the intended bacteria, the
remaining bacteria develop genes that make the bacteria resistant to further drug
treatments.125 Bacteria also possess the ability to give these drug resistant genes
to neighboring bacteria.126 Thus, the drug resistance spreads to all the surviving
bacteria.127 Resistant bacteria are found in livestock, meat, and people
worldwide.128 Farmers or doctors must find different or new antibiotics to
effectively treat illnesses caused by these drug-resistant bacteria.129 Bacteria that
are resistant to two or more antibiotics are called superbugs.130
Superbugs are a serious concern for the public health and medical community.
About two million people get sick from superbugs annually and, of those, about

https://www.fsis.usda.gov/wps/portal/fsis/topics/recalls-and-public-health-alerts/recallsummaries (last updated June 14, 2019).
120 Cassiday, supra note 46.
121 Id.
122 Mark Post, Cultured Meat from Stem Cells: Challenges and Prospects, 92 MEAT SCI.
297, 297 (2012).
123 Id.
124 Cassiday, supra note 46.
125 Jodi A. Lindsay & Matthew T.G. Holden, Understanding the Rise of the Superbug:
Investigation of the Evolution and Genomic Variation of Staphylococcus aureus, 6
FUNCTIONAL & INTEGRATIVE GENOMICS 186, 186 (2006).
126 Id.
127 Id.
128 Caroline Plante, In the Race to Fight Antibiotic Resistance, the Livestock Industry
Can Be a Game Changer, STAT (Jan. 12, 2017), https://www.statnews.com/2017/01/12/
antibiotic-resistance-livestock-industry/.
129 Laura Joszt, Slow Uptake Among Physicians of Effective Antibiotics to Treat
Superbugs, AJMC MANAGED MKTS. NETWORK (Aug. 27, 2019), https://www.ajmc.com/
focus-of-the-week/slow-uptake-among-physicians-of-effective-antibiotics-to-treatsuperbugs.
130 What’s at Stake: Overuse of Modern Antibiotics Has Given Rise to “Superbugs”—
Bacteria that Are Now Resistant to Numerous Antibiotics., NRDC, https://www.nrdc.org/
save-antibiotics?gclid=CjwKCAiAyeTxBRBvEiwAuM8dnbdK9UQqnNy5h-Thxsm
NA7_AB-DkwotFMeixCaXwpVXleSpBbxshNxoCNasQAvD_BwE (last visited Apr. 17,
2020).
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twenty-three thousand die from the pathogens.131 Therefore, coming up with
new treatments and new ways to keep bacteria out of the food chain is very
important.
As with normal pathogens, cell-based meats are not susceptible to superbugs
infiltrating the product.132 For example, Memphis Meats claims that neither
antibiotics nor growth hormones are required in its process because of the sterile
lab conditions.133 Therefore, there is no risk of antibiotic resistance being created
in cell-based meats because there is no introduction of antibiotics into the
product.134 In addition, sterile laboratory conditions eliminate the risk of any
superbug being in the food product itself.135 Thus, the growth of cell-based meats
would stop the cycle of creating food-based pathogens and eliminate the
introduction of superbugs into food.136
The sterile conditions in which the cell-based meats are grown, cultivated,
and processed reduce the risk of food-based pathogens.137 Not only do they
reduce the risk of these pathogens, but they also reduce the creation of bacteria
that are resistant to multiple antibiotics.138 The increased level of food safety
will put consumers at ease and save manufacturers money that would have gone
to the recall of their respective products.139
B. Novel Foods
Meats grown in a lab have the potential to be healthier than those that are
traditionally harvested.140 The manufacturers can alter the cell culture or a cell’s
genomic makeup so that cell-based meats would be fortified with beneficial
vitamins and fatty acids.141 For example, omega-3s found in fatty cold-water fish
could be produced by cow cells which would increase the nutritional value of

131 Stop the Spread of Superbugs: Help Fight Drug-Resistant Bacteria, NEWS IN HEALTH
(Feb. 2014), https://newsinhealth.nih.gov/2014/02/stop-spread-superbugs.
132 SPECHT & LAGALLY, supra note 87, at 2.
133 Cassiday, supra note 46; Marta Zaraska, Lab-Grown Meat Is in Your Future, and It
May Be Healthier than the Real Stuff, WASH. POST (Mar. 2, 2016), http://tinyurl.com/WPlabmeat.
134 Zaraska, supra note 133.
135 Cassiday, supra note 46; Zaraska, supra note 133.
136 Cassiday, supra note 46; Zaraska, supra note 133.
137 Cassiday, supra note 46; Zaraska, supra note 133.
138 Cassiday, supra note 46; Zaraska, supra note 133.
139 Cassiday, supra note 46.
140 Id.
141 Cellular Agriculture: The Future Food, NEW HARVEST, https://www.newharvest.org/cellular_agriculture (last visited Apr. 17, 2020) (showing examples of how
scientists have modified genes to produce other types of food and drink).
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the cow product.142 Even unhealthy saturated fats could be eliminated and
replaced with more healthy polyunsaturated fats.143 The combinations are
limitless. Theoretically, different genomes from different species’ cells could be
“combined to produce meat blends with new flavor, texture, and nutritional
profiles.”144
Researchers such as Liz Specht, a senior scientist at the Good Food Institute,
are confident that they can alter conditions so that they can produce healthier
meats, stating, “Clean meat version 1.0 involves recapitulating as quickly as
possible the products that consumers already know and love, but for version 2.0,
the question is, could we actually tailor the composition of these cells to make
them, for example, healthier?”145 Ms. Specht notes that it is possible to simply
infuse fatty acids by adding the compounds to the culture growth medium.146
Other nutrients may be effectively infused into the cell-based meat cells in a
similar fashion.147 Another way to add nutrients and fats to the cell-based meats
would be to genetically modify the cells so that they produce the specific
compound desired.148
III. THE STATE RESPONSE TO CELL-BASED MEATS
The response to cell-based meats has already begun on the state level. State
lawmakers have started to propose legislative action against cell-based meats in
order to protect their farmers. Bills have either been proposed or passed in
Montana,149 Kentucky,150 North Dakota,151 and Missouri.152 At least thirteen
state bills proposed in 2019 have to do with labeling requirements for cell-based
Zaraska, supra note 133.
Cassiday, supra note 46.
144 Id.
145 Id.
146 Id.
147 Id.
148 Id.
149 H.R. 327, 66th Leg., Reg. Sess. (Mont. 2019).
150 Don Sergent, House Bill Takes Aim at Lab-Grown Meat, BOWLING GREEN DAILY
NEWS (Feb. 25, 2019), https://www.bgdailynews.com/news/house-bill-takes-aim-at-labgrown-meat/article_f7738485-ddb4-5f23-b5c3-411ee485996b.html; Taylor Six, Lab Grown
or Livestock? HB311 to Require Labeling of Meats, RICHMOND REG. (Feb. 25, 2019),
https://www.richmondregister.com/news/lab-grown-or-livestock/article_58ed1f0a-86c05e40-b81c-7af0c25e3eeb.html.
151 Jenny Schlecht, Bill Defining Meat in North Dakota Goes to the Governor, Other
States Work on Similar Efforts, GRAND FORKS HERALD (Mar. 4, 2019),
https://www.grandforksherald.com/business/agriculture/981367-Bill-defining-meat-inNorth-Dakota-goes-to-the-governor-other-states-work-on-similar-efforts.
152 Zlati Meyer, Missouri Becomes First State to Regulate Use of the Word ‘Meat’, USA
TODAY (Aug. 28, 2018), https://www.usatoday.com/story/money/2018/08/28/animal-meatmissouri-law/1114285002/.
142
143
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meat products.153 In 2019, fourteen states total passed seventeen laws against
cell-based meat labels.154
House Bill 311 in Kentucky, which was proposed in late February 2019 and
signed into law on March 21, 2019, amended the state’s food labeling laws.155
A food product is now considered misbranded if “it purports to be or is
represented as meat or a meat product and it contains any cultured animal tissue
produced from in vitro animal cell cultures outside of the organism from which
it is derived.”156 This means that all cell-based meats would need to be explicitly
labeled as such on the packaging or the relevant company would face penalties
from the state for misbranding a food product.157 This is a preemptive strike
against cell-based meat companies and technology in order to protect Kentucky
farmers and “real” meats.158
Washington State has proposed a bill, the Natural Meat Protection Act, that
would criminalize the sale of cell-based meats and restrict funding for the
research of new technologies.159 The bill states that “(1) [a] person may not
advertise, sell, or offer for sale a cell-cultured meat product in the state of
Washington [and] (2) State funding may not be appropriated or expended to fund
research or development of cell-cultured meat product.”160 Lawmakers in
Washington have stated that they are concerned about the safety of the lab grown
product because the food product is untested.161 As of January 2020, the bill has
not made it out of the Washington House of Representatives.162

153 Greg Cima, Lawmakers Want to Restrict the Use of the Word ‘Meat’, AM.
VETERINARY MED. ASS’N (Feb. 27, 2019), https://www.avma.org/javma-news/2019-0315/lawmakers-want-restrict-use-word-meat.
154 E.g., H.R. 4245, 123rd Gen. Assemb., Reg. Sess. (S.C. 2019) (amending South
Carolina’s food labeling laws to make it illegal to represent clean meat as a “meat” product);
H.R. 327, 66th Leg., Reg. Sess. (Mont. 2019); H.R. 311, 2019 Leg., Reg. Sess. (Ky. 2019);
H.R. 1400, 2019 Leg., Reg. Sess. (N.D. 2019); S. 68, 65th Leg., Gen. Sess. (Wyo. 2019);
Megan Poinski, Cell-Based Meat Products Are Years Away, So Why Are States Making So
Many Laws About Them?, FOODDIVE (Feb. 12, 2020), https://www.fooddive.com/news/cellbased-meat-products-are-years-away-so-why-are-states-making-so-many-l/571071/.
155 Sergent, supra note 150; H.R. 311, 2019 Leg., Reg. Sess. (Ky. 2019); Six, supra note
150.
156 Sergent, supra note 150; Six, supra note 150; H.R. 311, 2019 Leg., Reg. Sess. (Ky.
2019).
157 Sergent, supra note 150; Six, supra note 150.
158 Sergent, supra note 150; Six, supra note 150.
159 H.R. 1519, 66th Leg., Reg. Sess. (Wash. 2019).
160 Id.
161 Nathaniel Popper, You Call That Meat? Not So Fast, Cattle Ranchers Say, N.Y.
TIMES (Feb. 9, 2019), https://www.nytimes.com/2019/02/09/technology/meat-veggieburgers-lab-produced.html.
162 Bill Information, WASH. ST. LEGISLATURE (Jan. 29, 2020), https://app.leg.wa.gov/
billsummary?BillNumber=1519&Year=2019&Initiative=false.
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Many farm trade organizations have been vocal against this new
technology.163 For example, Kentucky Agriculture Commissioner Ryan Quarles
commented on the Kentucky bill saying, “In a couple of years, lab-grown meat
will be available across America. . . . It’s important that we stand up and protect
our cattle farmers, and it’s important that consumers know the difference
between a steak that comes from a farm and a steak grown in a lab.”164 This
sentiment is generally shared by farm lobbyists.
Some of these bills are being challenged in court by the American Civil
Liberties Union (“ACLU”) and other faux meat groups like Tofurky, which
produces a tofu turkey substitute that might fall within the new labeling
requirements for cell-based meats.165 The challengers state that a new Missouri
law will only confuse the average consumer and discriminate against out-ofstate retailers.166 In addition, the challenge claims that “the law plays favorites
to benefit the meat industry, violates free-speech, … violates a law preventing
discrimination against out-of-state companies,” and is too vague to follow.167
Pro cell-based meat groups have responded to the states’ concerns by rallying
lobbyists and even sending a letter to President Trump in hopes of clarifying the
regulatory and legal issues surrounding the new technology.168 Sarah Sorscher,
the regulatory affairs representative for the Center for Science in the Public
Interest, challenges the idea that consumers will be confused by the labeling
laws.169 Ms. Sorscher said, “We think the issue of whether they use a term like
meat is a proxy for this bigger issue, which is that the meat industry is concerned
about competition from these products. . . . The bills don’t seem to be directed

163 E.g., U.S. CATTLEMEN’S ASS’N, PETITION FOR THE IMPOSITION OF BEEF AND MEAT
LABELING REQUIREMENTS: TO EXCLUDE PRODUCTS NOT DERIVED DIRECTLY FROM ANIMALS
RAISED AND SLAUGHTERED FROM THE DEFINITION OF “BEEF” AND “MEAT” (2018),
https://www.fsis.usda.gov/wps/wcm/connect/e4749f95-e79a-4ba5-883b-394c8bdc97a3/1801-Petition-US-Cattlement-Association020918.pdf?MOD=AJPERES.
164 Sergent, supra note 150; Six, supra note 150.
165 Popper, supra note 161; Lawsuit Raises the Stakes in Food Fight over the Term
“Meat”, ACLU MO. (Aug. 27, 2018), https://www.aclu-mo.org/en/news/lawsuit-raisesstakes-food-fight-over-term-meat; Complaint for Declaratory and Injunctive Relief, Tofurky
v. Soman, No. 4:19-cv-00514-KGB (E.D. Ark. July 22, 2019).
166 Chris Albrecht, Tofurky and the ACLU Go to the Meat-resses in Legal Dispute with
Missouri, SPOON (Aug. 28, 2018), https://thespoon.tech/tofurkey-and-the-aclu-go-to-themeat-resses-in-legal-dispute-with-missouri/; Complaint for Declaratory and Injunctive
Relief, supra note 165, at 1, 15.
167 Albrecht, supra note 166; Complaint for Declaratory and Injunctive Relief, supra
note 165.
168 Letter from Memphis Meats & N. Am. Meat Inst., to Donald J. Trump, U.S. President
(Aug. 23, 2018), https://static1.squarespace.com/static/5674c0c22399a3a13cbc3af2/t/
5b7edcd588251b2ccdb7fa47/1535040750340/Memphis+Meats+-+North+American+Meat+
Institute+letter.
169 Popper, supra note 161.
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at solving a problem in the marketplace. It is about fighting off competition.”170
Data showing that farming is becoming less viable supports Ms. Sorscher’s
position.171
IV. THE LAW: PATENT LAW, REGULATORY LAW, AND THE HATCHWAXMAN ACT
A. Patent Law in General
Intellectual property rights are granted to any original creation of the mind in
the fields of art, literature, or science to protect the work for a predetermined
period of time.172 IP rights are given to creators or inventors in the form of
copyrights, patents, trademarks, or trade secrets.173 These forms of protection
trace their roots back to England and are well ingrained in our society.174 IP
rights are essential in allowing the creator or manufacturer of a work to protect
his or her energy, time, and monetary investments that were poured into its
creation or process without the fear of a competitor using the creator’s
investments to undercut them in the marketplace.175
All patents must be novel, useful, and non-obvious.176 “Novel” means that the
invention has not been described in a published patent application or other
publication, nor in the market, before the submitted patent application.177 When
a patent is challenged, the claim of a novel patent can extend up to one year prior
to the submission of the patent application.178
When evaluating the term “useful,” the invention to be patented needs to have
a purpose.179 There are very few patent applications that have been denied
Popper, supra note 161.
Gholipour, supra note 88.
172 Saha & Bhattacharya, supra note 13, at 88.
173 Id.
174 Id.
175 See id.
176 General Information Concerning Patents, U.S. PAT. & TRADEMARK OFF. (Oct. 15,
2015), https://www.uspto.gov/patents-getting-started/general-information-concerningpatents.
177 Frequently Asked Questions on Patents, BROWN & MICHAELS,
http://www.bpmlegal.com/patqa.html (last visited Apr. 18, 2020); J. Lille Tidwell & Lance
A. Liotta, Inventions and Patents: A Practical Tutorial, 823 METHODS MOLECULAR
BIOLOGY 391, 392 (2012).
178 Frequently Asked Questions on Patents, supra note 177; see generally John Calvert,
The Provisional Patent Application: What You Need to Know, U.S. PAT. & TRADEMARK
OFF. (Apr. 2010), https://www.uspto.gov/learning-and-resources/newsletter/inventorseye/provisional-patent-application-what-you-need-know.
179 Frequently Asked Questions on Patents, supra note 177; General Information
170
171
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because the invention was not useful.180 Almost anything that someone seeks a
patent for does something that can be determined to be useful.181
Finally, the “not obvious” term means that the invention must be different or
not obviously the same as what has come before the thing seeking to be
patented.182 The standard of judgment is from the perspective of “an ordinary
person skilled in the applicable field.”183 In other words, the invention is obvious
if a person, who knows the ins and outs of a certain field, “would have known
to combine previously-existing inventions to result in your invention, without
having seen your patent application first.”184
The cell-based meat manufacturers will obtain patents on a number of
processes and cell lines.185 With the average patent application timeline lasting
twenty-one months,186 the manufacturers will have to plan for what they seek
patents on and how they will patent their ideas.187 When seeking patents, there
are two types of patents that these meat manufacturers can obtain: utility patents
and design patents.188
Utility patents cover machines, manufactured articles, processes, chemicals,
cells lines, or any combination of these.189 Utility patents last for at least twenty
years from the initial filing or earliest priority date in a patent application to the
United States Patent and Trademark Office (“USPTO”).190 However,
maintaining these types of patents is not free.191 Maintenance fees are paid
Concerning Patents, supra note 176.
180 Frequently Asked Questions on Patents, supra note 177; see generally Usefulness,
JUSTIA, https://www.justia.com/intellectual-property/patents/patentability-requirements/
usefulness/ (last updated June 2019).
181 Frequently Asked Questions on Patents, supra note 177; see generally Michael Risch,
Reinventing Usefulness, 2010 B.Y.U. L. REV. 1195, 1200.
182 Frequently Asked Questions on Patents, supra note 177; General Information
Concerning Patents, supra note 176.
183 Frequently Asked Questions on Patents, supra note 177; Gregory Mandel, The NonObvious Problem: How the Indeterminate Nonobviousness Standard Produces Excessive
Patent Grants, 42 U.C. DAVIS L. REV. 57, 59 (2008).
184 Frequently Asked Questions on Patents, supra note 177; Mandel, supra note 183, at
59.
185 Robert Yaman, Cell-Based Meat Patent Analysis Part 1: Memphis Meats and Just,
ROBERT YAMAN (Sept. 2, 2018), https://www.robertyaman.com/blog/clean-meat-patentanalysis-part-1.
186 How Long Does It Take to Get a Patent?, ERICKSON L. GROUP, PC,
http://www.ericksonlawgroup.com/law/patents/patentfaq/how-long-does-it-take-to-get-apatent/ (last visited Apr. 18, 2020); see generally December 2019 Patents Data, at a Glance,
U.S. PAT. & TRADEMARK OFF. (Dec. 2019), https://www.uspto.gov/dashboards/patents/
main.dashxml (demonstrating the average patent application timeline in December 2019).
187 See generally How Long Does It Take to Get a Patent?, supra note 186.
188 See generally General Information Concerning Patents, supra note 176.
189 Id.
190 Id.
191 See Maintain Your Patent, U.S. PAT. & TRADEMARK OFF., https://www.uspto.gov/
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throughout the life of a utility patent.192 If the fees are not paid, the patent will
expire earlier than the twenty-year term.193
Design patents are granted to the holder when the aesthetic configuration of
the patented object is novel, useful, and not obvious.194 A design patent does not
cover the function or construction of the invention like its utility patent
counterpart.195 As of 2015, they are valid for a period of fifteen years from the
date of issue.196 Unlike utility patents, there are no maintenance fees required to
maintain the validity of design patents.197
After a patent expires, the invention is freely available to all.198 Therefore, it
is incredibly important for the holder to use the duration of the patent as
efficiently as they can or they risk losing potential profits from being the sole
provider of the product or licensing the subject of the patent to others.199
A manufacturer or inventor cannot seek a patent on the following: processes
that are purely mental;200 mathematical algorithms or formulas that do not have
a real-world effect, although, “a formula or algorithm may be claimed as part of
a method”;201 arrangements of printed words;202 naturally occurring things that
have not been changed;203 and the underlying principle to a device or method

patents-maintaining-patent/maintain-your-patent (last visited Apr. 18, 2020).
192 See id.
193 Patent Maintenance Fees: Everything You Need to Know, UPCOUNSEL,
https://www.upcounsel.com/patent-maintenance-fees (last visited Apr. 18, 2020); Maintain
Your Patent, supra note 191.
194 General Information Concerning Patents, supra note 176.
195 Id.
196 Patent Term Calculator, U.S. PAT. & TRADEMARK OFF., https://www.uspto.gov/
patent/laws-and-regulations/patent-term-calculator (last visited Apr. 18, 2020).
197 Joe Stone, What Is a Lifespan of a Patent?, CHRON, https://smallbusiness.chron.com/
lifespan-patent-55972.html (last visited Apr. 18, 2020); Maintain Your Patent, supra note
191.
198 General Information Concerning Patents, supra note 176; Beverly Bird, What
Happens to a Patent When It Expires?, LEGAL ZOOM, https://info.legalzoom.com/happenspatent-expires-20317.html (last visited Apr. 19, 2020).
199 General Information Concerning Patents, supra note 176; Bird, supra note 198.
200 What Does a Patent Do: Everything You Need to Know, UPCOUNSEL,
https://www.upcounsel.com/what-does-a-patent-do (last visited Apr. 19, 2020); see
generally Pamela Samuelson, Benson Revisited: The Case Against Patent Protection for
Algorithms and Other Computer Program-Related Inventions, 39 EMORY L.J. 1025, 1034–
37 (1990).
201 How to Read an Office Action, BROWN & MICHAELS, http://www.bpmlegal.com/
howtooa3.html (last visited Apr. 19, 2020); see generally Samuelson, supra note 200, at
1034–37.
202 How to Read an Office Action, supra note 201; see generally Samuelson, supra note
200, at 1034–37.
203 How to Read an Office Action, supra note 201; see generally Samuelson, supra note
200, at 1034–37.
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which, based on new scientific principles, cannot be patented.204 Manufacturers
of cell-based meats will have to walk a fine line in order to prove that cell-based
meats do not merely involve a formula or a naturally occurring thing, but rather
involve an object or process that can be patented so that they can keep their
products protected.205
The patents sought for cell-based meat products could be both utility and
design patents.206 The utility patents will be for the manufacturing processes of
the cell-based meats, the machines used in the process, the cell lines, and the
chemicals used throughout the process.207 Even though there is not much use for
design patents in this field, there will be applications tied to how the finished
meat products look.208 Eventually, the manufacturers will want to design the
meat to look like T-bone steaks or real chicken breast;209 therefore, the
manufacturers will want to have patents on those specific designs.210
It is generally understood that the stronger the protections available, the better
these creations of the mind can be protected.211 Specifically, strong patent laws
for biotechnology creations create more incentives for research and more
opportunities for securing funding, which can lead to earlier discoveries.212 In
addition, stronger biotechnology patent laws create greater public awareness of
the invention because patents are disclosed to the public; this further drives the
funding and incentives to create new technologies.213
204 What Does a Patent Do, supra note 200; Andrew A. Schwartz, The Patent Office
Meets the Poison Pill: Why Legal Methods Cannot Be Patented, 20 HARV. J.L. & TECH. 333,
354 (2007).
205 Yaman, supra note 185.
206 Utility Patent vs. Design Patent: Everything You Must Know, UPCOUNSEL,
https://www.upcounsel.com/utility-patent-vs-design-patent (last visited Apr. 19, 2020)
(explaining the difference between the two types of patents); Lawrence O. Gostin &
Benjamin E. Berkman, Pandemic Influenza: Ethics, Law, and the Public’s Health, 59
ADMIN. L. REV. 121, 134 (2007).
207 Utility Patent vs. Design Patent: Everything You Must Know, supra note 206; Lars
Noah, Managing Biotechnology’s [R]evolution: Has Guarded Enthusiasm Become Benign
Neglect, 11 VA. J.L. & TECH. 1, 39 (2006).
208 Utility Patent vs. Design Patent: Everything You Must Know, supra note 206; Bijal
Vakil, Design Patents: A Growing Trend in the Hardware, WHITE & CASE (July 29, 2019),
https://www.whitecase.com/publications/article/design-patents-growing-trend-hardwarespace.
209 Clara Rodríguez Fernández, Beyond the Lab-Grown Burger: ‘Cellular Agriculture’ Is
Taking over the Food Industry, LABIOTECH (Apr. 9, 2019), https://labiotech.eu/features/
cellular-agriculture-food-industry/ (explaining that some startups have taken on the
challenge of designing cell-based meats to look like the traditional counterpart).
210 Craig Allen Nard, Legal Forms and the Common Law of Patents, 90 B.U. L. REV. 51,
93–94 (2010).
211 The Economic Case for a Strong Patent System, SAVE THE AM. INVENTOR (Nov. 12,
2013), https://www.savetheinventor.com/blog/economic-case-strong-patent-system.
212 Johnston, supra note 12.
213 Id.
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However, strong patent laws are not without a number of disadvantages as
well.214 For example, biomedical research and methods may be restricted
broadly by creating a fee that researchers must first pay.215 Another disadvantage
is that the patent incentives are wiped out if the market is not profitable.216 A
disadvantage that is also noticeable is the cost of health care may be driven up
if patent holders charge excessive prices for the use of their respective
inventions.217
A strong patent system will drive a certain industry to create more and will
boost the economy of that industry.218 However, this may cause a product to
become unobtainable by the low-income population.219 A weaker protection
system allows for many players to compete in the same industry, which makes
a product more widely available and affordable.220 Thus, regulators must walk a
fine line in order to promote the economy of an industry, while also ensuring
products are not out of reach for some of the population due to high prices.221
A recent example of how strong patent laws can cause problems in biomedical
research occurred with the BRCA2 gene.222 The BRCA2 gene is a well-known
gene that, when mutated, will eventually cause breast cancer.223 Even though it
was very sought after, only one company, Myriad Genetics, held the rights to

214 Advantages and Disadvantages of Patents, UPCOUNSEL,
https://www.upcounsel.com/advantages-and-disadvantages-of-patents (last visited Apr. 19,
2020); Robert E. Thomas, Vanquishing Copyright Pirates and Patent Trolls: The Divergent
Evolution of Copyright and Patent Laws, 43 AM. BUS. L.J. 689, 703 (2006).
215 Emily A Largent & Holly Fernandez Lynch, Paying Research Participants:
Regulatory Uncertainty, Conceptual Confusion, and a Path Forward, 17 YALE J. HEALTH
POL’Y L. & ETHICS 61, 102 (2017).
216 Id. at 75.
217 Id. at 87.
218 The Patent System: Economic Benefits of the Patent System, AUSTRALIAN L. REFORM
COMMISSION, https://www.alrc.gov.au/publications/2-patent-system/economic-benefitspatent-system (last updated Aug. 2, 2010); Michael J. Malinowski & Maureen A. O’Rourke,
A False Start - The Impact of Federal Policy on the Genotechnology Industry, 13 YALE J.
ON REG. 163, 214 (1996).
219 Gaston Kroub, The Cost of a Cure: Patent Rights and Drug Prices, ABOVE THE L.
(June 6, 2017), https://abovethelaw.com/2017/06/the-cost-of-a-cure-patent-rights-and-drugprices/; Marie F. Kuczmarski, Beverage Consumption Patterns of a Low-Income
Population, NCBI (Oct. 20, 2010), https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC2957908/.
220 Kroub, supra note 219; Lital Helman & Gideon Parchomovsky, The Best Available
Technology Standard, 111 COLUM. L. REV. 1194, 1210 (2011).
221 R. SHERMER & CO., INTELLECTUAL PROPERTY: CHALLENGES FACED DURING
DIVESTITURES FROM THE MONITOR/TRUSTEE’S PERSPECTIVE 1, 7, http://rshermer.com/
images/Intellectual_Property_v2.0.pdf.
222 E. Richard Gold & Julia Carbone, Myriad Genetics: In the Eye of the Policy Storm,
12 GENETICS MED. S39, S39, S43–S44 (2010).
223 Id.
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the gene due to extremely strong IP protections.224 Anyone who wanted to
research breast cancer and the BRCA2 gene had to either obtain permission from
this company or use their services.225 This led to scarcely any research being
done on breast cancer, outside of Myriad Genetics, because the company was
charging an obscene amount to allow others to use the gene in their research.226
This monopoly alone hindered an entire area of cancer research across the
nation.227
Eventually, a lawsuit was brought against Myriad Genetics by the Association
of Molecular Pathology.228 The suit by the Association of Molecular Pathology
alleged that Myriad Genetics’ patents were invalid.229 Specifically, the
association alleged that the naturally occurring products of nature, such as
specific isolated genes, were unpatentable and that the diagnostic and screening
tests were just basic procedures of science that did not yield any real-world
transformations.230 United States law defines patent eligible to include “any new
and useful process, machine, manufacture, or composition of matter, or any new
and useful improvement thereof.”231 However, if the property falls under an
excluded category, such as a “naturally occurring article,” as defined in case law,
then it is not patent eligible.232
Association for Molecular Pathology v. United States Patent and Trademark
Office233 led to important cases, such as Genetic Technicians v. Bristol-Myers
Squibb Co., which defined intellectual property rights for genes and other
biotechnologies.234 In Association for Molecular Pathology, the court held that
any naturally occurring gene may not be eligible for patent rights;235 however,
if the gene were to be modified in some way from how it occurs naturally, then
there may be IP rights given to the creator.236 Therefore, if a gene matches
molecule for molecule what one could find naturally occurring in the wild, then
224 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 587 (2013);
Lorelei Ritchie de Larena, The Price of Progress: Are Universities Adding to the Cost., 43
HOUS. L. REV. 1373, 1418 (2007).
225 Ass’n for Molecular Pathology, 569 U.S. at 584–85.
226 Gold & Carbone, supra note 222, at S39, S43–S44.
227 Id.
228 Ass’n for Molecular Pathology, 569 U.S. at 576.
229 Id. at 596.
230 Id. at 595.
231 35 U.S.C. § 101 (2012).
232 Ass’n for Molecular Pathology, 569 U.S. at 580; Mayo Collaborative Servs. v.
Prometheus Labs., Inc., 566 U.S. 66, 70 (2012).
233 Ass’n for Molecular Pathology, 569 U.S. at 581, 587.
234 Genetic Techs. Ltd. v. Bristol-Myers Squibb Co., 72 F. Supp. 3d 521, 531, 536 (D.
Del. 2014) (citing Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576,
576 (2013)).
235 Ass’n for Molecular Pathology, 569 U.S. at 580.
236 Id. at 590–91.
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one cannot stake a claim to it.237 The scientists had to actually change something
in the DNA code in order to establish a patent claim.238
The rule related to gene patenting has been transferred not just to sequences
of DNA, but also to patenting entire cell lines.239 Essentially, one may patent a
cell line if he or she can show that it satisfies the initial definition of a patent—
novel, useful, and non-obvious—and that the cell line was created artificially.240
Currently, there are over two thousand patented cell lines.241 In Sherley v.
Sebelius, two scientists questioned various stem cell lines after President Obama
expanded the ability of researchers to use different lines of stem cells.242
More often, the courts will see suits over the patented process of creating and
maintaining a cell line. For example, the United States Court of Appeals for the
Federal Circuit in Pharmastem Therapeutics, Inc. v. Viacell, Inc.243 oversaw a
challenge to a patented method of extracting stem cells from the umbilical cord,
cryogenically freezing those cells, and then later thawing those stem cells for
use.244 These living cells can be difficult to work with and keep alive, so finding
techniques to preserve, feed, and keep the cells viable for experimentation
becomes more important than protecting the cell line itself.245 If the cells cannot
be kept alive, what is the point in patenting the line in the first place? A large
focus of all scientists, whether in a specific industry or at a university, is on the
process of how to work with their cell lines.246
This concept is extremely important for cell-based meat because the stem
cells that will eventually become the meat or fat will need to be kept alive and
viable to become the product.247 Also, the same stem cells may be edited for
faster growth or to produce vitamins, and the scientists will want to protect their
Id. at 577, 594.
Id. at 587.
239 Jon F. Merz & Mildred K. Cho, What Are Gene Patents and Why Are People Worried
About Them?, 8 COMMUNITY GENETICS 203, 206 (2005).
240 Id. at 204–06.
241 Cellosaurus Search Result, CELLOSAURUS, https://web.expasy.org/cgi-bin/
cellosaurus/search?input=patent (last visited Apr. 19, 2020) (showing a search result of
2,307 patents on cell lines).
242 Sherley v. Sebelius, 776 F. Supp. 2d 1, 4, 7 (D.D.C. 2011).
243 Pharmastem Therapeutics, Inc. v. Viacell, Inc., 491 F.3d 1342, 1346 (Fed. Cir. 2007).
244 Id. at 1366 (discussing a patent issue around a certain strain of stem cells).
245 Id. at 1347.
246 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 581–82
(2013); Pharmastem Therapeutics, 491 F.3d at 1348; Genetic Techs. Ltd. v. Bristol-Myers
Squibb Co., 72 F. Supp. 3d 521, 532, 534–35 (2014); Gold & Carbone, supra note 222, at
S43–S44; Merz & Cho, supra note 239, at 204–05.
247 Ginger Hultin, Lab-Grown Meat: Exploring Potential Benefits and Challenges of
Cellular Agriculture, FOOD & NUTRITION (Feb. 27, 2017),
https://foodandnutrition.org/march-april-2017/lab-grown-meat-exploring-potential-benefitschallenges-cellular-agriculture/.
237
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specific lines of cell-based meat.248 Overall, the scientists will want to protect
the specific processes by which they create products.249
In addition, the cell-based meat lines, when naturally in their host animal,
have all the nutrients and support systems of that animal to thrive.250 These
consist of things such as vitamins and nutrients, a constant flow of oxygen, and
a medium to grow in.251 Therefore, the scientists will have to replicate this
environment to keep the cells happy and thriving.252 This will also take specific
processes that they will want to patent and protect.253
B. Regulatory Oversight
There has been much dispute as to which regulatory agency will oversee cellbased meat production.254 As of late October 2018, the FDA and the USDA have
decided to share this responsibility.255 The FDA will have regulatory oversight
over good manufacturing practices, the quality of the food, labeling, and every
other major food regulation that would apply under the Food, Drug, and
Cosmetic Act (“FDCA”).256 Under this agreement, the USDA will have
regulatory authority over harvesting and marketing.257
The FDA will have regulatory oversight over the food product of cell-based
meats.258 This authority comes from 21 U.S.C. § 321 within the FDCA.259 Under
FDA law, there is no debate over whether cell-based meat is considered food.260
The term “food” means: “any articles used for food or drink for man or other
animals, chewing gum, and articles used for components of any such article.”261
Even as circular as this definition is, there is no doubt that cell-based meats are

Id.
See Gold & Carbone, supra note 222, at S39.
250 Neil Stephens et al., Bringing Cultured Meat to Market: Technical, Socio-Political,
and Regulatory Challenges in Cellular Agriculture, 78 TRENDS IN FOOD SCI. & TECH. 155,
160 (2018).
251 Id. at 159.
252 Id. at 158–59.
253 Id. at 158.
254 John Dillard, Who Will Regulate Lab-Grown Meat?, DROVERS (Dec. 11, 2018),
https://www.drovers.com/article/john-dillard-who-will-regulate-lab-grown-meat.
255 Sam Bloch, Dispatch from D.C.: USDA and FDA Agree to Jointly Regulate CellCultured Meat. And Yes, It’s Meat, NEW FOOD ECON. (Oct. 25, 2018),
https://newfoodeconomy.org/usda-fda-lab-grown-cell-cultured-joint-regulation/.
256 See id.; see also Federal Food, Drug, and Cosmetics Act, 21 U.S.C. §§ 301–399i
(2012).
257 Bloch, supra note 255.
258 Id.
259 See 21 U.S.C. § 321 (2012).
260 Bloch, supra note 255.
261 21 U.S.C. § 321(f) (2012).
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to be used for food.262
A company looking to get their cell-based meat approved for consumption
will have to address any additives it puts in its product.263 The term “food
additive” under the FDCA means:
Any substance, the intended use of which results or may reasonably
be expected to result, directly or indirectly, in its becoming a
component or otherwise affecting the characteristics of any food
(including any substance intended for use in producing,
manufacturing, packing, processing, preparing, treating, packaging,
transporting, or holding food; and including any source of radiation
intended for any such use).264
An additive in this process could be the recombinant DNA, the growth
medium of the cells, or the other nutrients the cells need to become meat
proteins.265 Each of these could easily be understood as a substance which
becomes a component of the food.266 For example, the company may want to
manufacture cell-based beef that has extra vitamin A, C, and D to provide for a
better-balanced diet.267 The company can do this either by adding extra vitamins
to the growth medium or by adding recombinant DNA to the cells so that the
cells produce the vitamins themselves.268 In order to use this process, the
manufacturers will need to get approval from the FDA under the food additive
provisions because both of the additives become a component of the food.269
Another approval that companies may need from the FDA is processed food
approval.270 The term “processed food” means: “any food other than a raw
agricultural commodity and [this] includes any raw agricultural commodity that
has been subject to processing, such as canning, cooking, freezing, dehydration,
or milling.”271 This is not an exhaustive list and what is considered “processed”
Bloch, supra note 255.
See 21 U.S.C. § 321(s) (2012).
264 Id.
265 VALENTIN WASCHULIN & LIZ SPECHT, GOOD FOOD INST., CELLULAR AGRICULTURE:
AN EXTENSION OF COMMON PRODUCTION METHODS FOR FOOD 1, 16–17 (2018),
https://www.gfi.org/images/uploads/2018/03/Cellular-Agriculture-for-Animal-Protein.pdf.
266 See generally 21 U.S.C. § 321(s) (2012) (defining what constitutes a food
component).
267 Muhammad Sajid Arshad et al., Tissue Engineering Approaches to Develop Cultured
Meat from Cells: A Mini Review, 3 COGENT FOOD & AGRIC. 1, 3 (2017).
268 Stephens et al., supra note 250, at 202; Determining the Regulatory Status of a Food
Ingredient, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/food/ingredientspackaging
labeling/foodadditivesingredients/ucm228269.htm (last visited Apr. 19, 2020).
269 Stephens et al., supra note 250, at 202; Determining the Regulatory Status of a Food
Ingredient, supra note 268.
270 See 21 U.S.C. § 321(gg) (2012).
271 Id.
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is up for interpretation by the FDA.272 Here, there could be a debate over whether
or not cell-based meats are considered “raw agricultural commodities.”273 A raw
agricultural commodity is defined as, “any food in its raw or natural state,
including all fruits that are washed, colored, or otherwise treated in their
unpeeled natural form prior to marketing.”274 They may be considered raw
agricultural commodities because the manufacturers grow the raw cells up from
the primary material, much like plants are grown from seeds.275 However,
because these meats are going through many different processes like packaging,
freezing, and antibacterial or antifungal treatments, it would be easy for the FDA
to find that these are “processed foods.”276 Under the FDCA, a processed food
is any food that is processed for consumption.277
C. Hatch-Waxman Primer
The FDA is unique as a regulatory agency because it has the legal framework
available to handle any safety and IP challenges to cell-based meat.278 When it
comes to patent rights, the FDA has a special statute called the Hatch-Waxman
Act, codified at 21 U.S.C. § 355; it modified the FDCA and was formally known
as the Drug Price Competition and Patent Term Restoration Act.279 HatchWaxman was a bipartisan effort undertaken by a Republican Senator from Utah
and a Democratic Representative from California.280 The act was enacted with a
few goals in mind; specifically, as the FDA stated, “[The] main goal . . . in this
area is to promote innovation, while also promoting rapid access to low-cost,
safe and effective generic drugs.”281 It represents a bargain between the pioneer
drug and the generic drug industries.282
272 Id.; see 21 U.S.C. § 341 (2012) (granting the Secretary authority to define reasonable
standards of identity and quality); 21 C.F.R. § 110.80 (2019) (defining the criteria for food
production).
273 21 U.S.C. § 321(r) (2012).
274 Id.
275 21 C.F.R. § 1.227 (2019).
276 See 21 C.F.R. § 1.227(2) (2019).
277 21 U.S.C. § 321(gg) (2012).
278 RENU LAL, CDER SMALL BUS. & INDUS. ASSISTANCE, U.S. FOOD & DRUG ADMIN.,
PATENTS AND EXCLUSIVITY 1 (2015), https://www.fda.gov/downloads/Drugs/Development
ApprovalProcess/SmallBusinessAssistance/UCM447307.pdf.
279 See 21 U.S.C. § 355 (2012); Hatch-Waxman Letters, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-letters
(last visited Apr. 20, 2020).
280 Erik Neumann, How Sen. Orrin Hatch Changed America’s Health Care, HEALTH
LEADERS (Jan. 2, 2019), https://www.healthleadersmedia.com/strategy/how-sen-orrin-hatchchanged-americas-health-care.
281 Colleen Kelly, The Balance Between Innovation and Competition: The HatchWaxman Act, the 2003 Amendments, and Beyond, 66 FOOD & DRUG L.J. 417, 436 (2011).
282 PETER BARTON HUTT ET AL., FOOD AND DRUG LAW: CASES AND MATERIALS 1000 (4th
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Moreover, Congress wanted to help companies get their generic drugs to
market faster and to overrule Roche Products, Inc. v. Bolar.283 In Roche
Products, Inc., the United States Court of Appeals for the Federal Circuit held
that even testing a generic drug to prepare it for FDA approval while the brand
drug’s patent was still in effect was patent infringement under 35 U.S.C. §
271.284 This meant that companies that wanted to create a generic drug had to
wait until the corresponding brand drug’s patent had expired before they could
start trials or testing for purposes of the FDA’s New Drug Approval (“NDA”)
process.285
Prior to the enactment of Hatch-Waxman, FDA officials developed a policy
for the approval of abbreviated NDAs in 1962.286 The policy change required
that, before introduction into interstate commerce, evidence that all new drugs
be “safe and effective for their intended use and recognized by the FDA as
such.”287 The “safe and effective” requirement must be proven by an “adequate
and well-controlled” clinical study.288 This FDA approval with the safe and
effective designation constituted part of the NDA process.289
Generic drug approval depends on when the FDA approves the brand drug’s
NDA.290 A generic drug applicant could apply for approval with a “paper
NDA.”291 An NDA applicant using a paper NDA relies upon data from
“published scientific literature” to demonstrate effectiveness of the generic
product, as well as the brand drug approved application.292 However, testing can
take years to complete, and an exuberant amount of money must be spent to get
FDA approval of these NDAs.293 In the past, this caused extensive delays in
getting to market, which cost manufacturers money.294 Generic drug

ed. 2014).
283 Id.; see Roche Prods., Inc. v. Bolar Pharm. Co., 733 F.2d 858 (Fed. Cir. 1984).
284 Roche Prods., Inc., 733 F.2d at 863.
285 Id. at 864; Kelly, supra note 281, at 424 (stating that the Hatch-Waxman Act revised
portions of the patent laws and overturned Roche Products, which considered filing an
ANDA too early as patent infringement).
286 Erika Lietzan, ANDAs Before Hatch-Waxman, OBJECTIVE INTENT (Aug. 19, 2017),
https://objectiveintent.blog/2017/08/19/andas-before-hatch-waxman/; The Hatch-Waxman
Act: A Primer, EVERYCRSREPORT.COM (Sept. 28, 2016),
https://www.everycrsreport.com/reports/R44643.html#_Toc463343270.
287 See 21 U.S.C. § 355(d) (2012).
288 See id.
289 The Hatch-Waxman Act: A Primer, supra note 286; 21 U.S.C. § 355 (2012).
290 The Hatch-Waxman Act: A Primer, supra note 286.
291 Id.; 21 U.S.C. § 355.
292 The Hatch-Waxman Act: A Primer, supra note 286; 21 U.S.C. § 355.
293 The Hatch-Waxman Act: A Primer, supra note 286; 21 U.S.C. § 355.
294 The Hatch-Waxman Act: A Primer, supra note 286; 21 U.S.C. § 355.
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manufacturers were dissatisfied with their disadvantage in the marketplace.295
If generic manufacturers did not want to pursue a paper NDA, then these
manufacturers had to submit a full NDA.296 Therefore, many brand drugs would
go without a generic counterpart because of the risks of patent infringement,
financial loss, and generic drug manufacturers being outcompeted by other
generic drug manufacturers.297 These risks and this fear of generic drug
manufacturers created an artificial extension to the exclusivity period for the
brand name drug manufacturers that was taken advantage of but was not
intended by IP laws.298
Pioneer manufacturers, meanwhile, were frustrated that the patent life of a
product was consumed by a lengthy regulatory process.299 The pioneer
manufacturers could not legally market their respective drugs without FDA
approval, which increased the overall market frustration.300 Both the pioneer
brand manufacturers and the generic drug manufacturers turned to Congress for
help.301
Under the 1984 Hatch-Waxman Act,302 the FDA may approve a generic drug
version’s abbreviated NDA (“ANDA”) after: “(1) all relevant product and use
patents have expired for the pioneer drug and (2) all relevant periods of market
exclusivity for the pioneer drug have also expired.”303 If these conditions are
met, then a generic drug may be submitted for approval if the generic version is
the same as the pioneer drug in all material respects.304 In these cases, all a
generic manufacturer must do to receive the FDA’s approval is submit the
ANDA, no “further consideration about the safety and effectiveness of the
generic [drug]” is required.305 This is because if the generic drug is the same as
the pioneer drug which already showed safety and efficacy through the NDA,
then there is no need to demonstrate safety and effectiveness again.306
If, however, the generic drug does differ from its pioneer counterpart (such as
by having a different active ingredient, dosage strength, or form), then the

The Hatch-Waxman Act: A Primer, supra note 286; 21 U.S.C. § 355.
The Hatch-Waxman Act: A Primer, supra note 286; 21 U.S.C. § 355.
297 The Hatch-Waxman Act: A Primer, supra note 286.
298 Id.; 21 U.S.C. § 355.
299 HUTT ET AL., supra note 282, at 1001.
300 Id.
301 The Hatch-Waxman Act: A Primer, supra note 286; 21 U.S.C. § 355.
302 21 U.S.C. § 355.
303 HUTT ET AL., supra note 282, at 1001; 21 U.S.C. § 355.
304 HUTT ET AL., supra note 282, at 1001.
305 Id.
306 Id.; FDA Ensures Equivalence of Generic Drugs, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/drugs/resources-you-drugs/fda-ensures-equivalence-generic-drugs (last
visited Apr. 20, 2020).
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generic drug applicant must submit a “suitability petition” to the FDA.307 The
petition needs to demonstrate that the difference between the drug and the
pioneer drug is not enough to preclude ANDA approval and that no additional
studies are needed to show safety and efficacy.308 This compromise allows a
generic drug company to use the innovator’s data in its submission, substantially
cutting costs to generic drug manufacturers.309
In return for allowing generic manufacturers to use the pioneer drug data to
support the ANDAs, the pioneer manufacturers receive patent-term extensions
and market exclusivity.310 The terms of a patent may be extended to compensate
a patent owner when a FDA-regulated review has caused a delay in using that
patent in the marketplace after it has been issued.311 The length of the extension
depends on how long the regulatory review periods last.312 For example, the
regulatory review periods for a new drug include the testing phase and the
agency approval phase.313 A drug manufacturer will submit the required
Investigational New Drug (“IND”) application before pre-clinical testing is
performed to determine if the drug is reasonably safe for humans;314 the period
between when the IND and the NDA are filed is the testing phase.315
The period between filing the NDA and the FDA’s approval is considered the
approval phase.316 The testing phase of a drug approval can last up to nine
years,317 and the average approval phase normally lasts less than two
years.318 The patent term extension is calculated by first reducing the extension
by any time that the applicant did not act with due diligence during the approval
phase, which is based on a finding by the FDA.319 After the calculated time, if
any, has been subtracted for a lack of due diligence, “one-half of the time
307 HUTT ET AL., supra note 282, at 1001; FDA Ensures Equivalence of Generic Drugs,
supra note 306.
308 HUTT ET AL., supra note 282, at 1001; U.S. FOOD & DRUG ADMIN., MANUAL OF
POLICY AND PROCEDURES: ANDA SUITABILITY PETITIONS 1 (2018), https://www.fda.gov/
media/86656/download.
309 HUTT ET AL., supra note 282, at 1001.
310 Id.
311 See 35 U.S.C. § 156(a)(4) (2012).
312 See id. § 156(c).
313 See id. § 156(g)(1)(B)(i)–(ii).
314 21 C.F.R. § 312.1(a) (2004); Investigational New Drug (IND) Application, U.S. FOOD
& DRUG ADMIN., https://www.fda.gov/drugs/types-applications/investigational-new-drugind-application (last visited Apr. 20, 2020).
315 See 35 U.S.C. § 156(g)(1)(B)(i) (2012).
316 See id. § 156(g)(1)(B)(ii).
317 Dennis S. Fernandez et al., The Interface of Patents with the Regulatory Drug
Approval Process and How Resulting Interplay Can Affect Market Entry, IN IPHANDBOOK
OF BEST PRACTICES 965–66 (2007).
318 Id.
319 35 U.S.C. § 156(c)(1) (2012).
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remaining in the testing phase would be added to the time remaining in the
approval phase”320 and that time is given as an extension to the patent.321
V. CAUTIONS FOR USING THE HATCH-WAXMAN ACT AS A MODEL
The Hatch-Waxman Act has solved several issues when it comes to providing
more generic drugs as a low-cost alternative to the average consumer.322
However, the Hatch-Waxman Act contains a few loop-holes and workarounds
that brand companies can abuse to make profits and delay the introduction of the
generic version of a drug.323 Brand drug companies will engage in actions such
as reverse payments, citizen petitions, and product hopping in order to find loopholes or circumvent the Hatch-Waxman Act.324 By recognizing the ways in
which these companies have taken advantage of this act, Congress and
regulatory agencies can incorporate better language into legislation and
formulate rules that prevent brand cell-based meat companies from delaying
competitors from entering the market and holding a monopoly.325
A. Reverse Payments
The first and most common way brand companies circumvent the HatchWaxman Act is through reverse settlement payments or simply reverse
payments.326 Reverse payments are used to pay off generic drug filers seeking
to enter a specific drug space.327 Once generic drugs enter the market, they
quickly take up a large portion of the market, cutting into brand companies’
profits.328 To continue making profits on their drugs, brand companies will pay

320 See id. § 156(c)(2); Small Business Assistance: Frequently Asked Questions on the
Patent Term Restoration Program, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/drugs/
cder-small-business-industry-assistance-sbia/small-business-assistance-frequently-askedquestions-patent-term-restoration-program (last updated Feb. 4, 2020).
321 See 35 U.S.C. § 156(c)(2).
322 Danielle Perini & Katherine Vogel Anderson, How Generic Drugs Are Made, U.S.
PHARMACIST (June 21, 2013), https://www.uspharmacist.com/article/how-generic-drugs-aremade.
323 Kieran Meagher, Abuse of the Hatch-Waxman Act: Mylan’s Ability to Monopolize
Reflects Weakness, 11 BROOK. J. CORP. FIN. & COM. L. 589, 590 (2017).
324 Id.
325 See id. at 614.
326 Id. at 596–97; Steven Adamson, Pharmaceutical Patent Wars, Reverse-Payment
Settlements, and Their Anticompetitive Effects for Consumers, 30 LOY. CONSUMER L. REV.
241, 252 (2018).
327 Meagher, supra note 323, at 589, 596–97.
328 Id. at 596 (stating that once generics enter the market, they can occupy up to 44
percent of the given area).
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generic filers to delay entering the market.329 The brand companies can legally
do this by suing the generic manufacturers for patent infringement, regardless of
the validity of the suits, and then settling quickly with the generic
manufacturers.330 In fact, reverse payment settlements actually “cost American
consumers anywhere between $0.6 billion and $7.5 billion each year, or $3.5
billion each year on average.”331
The concern for the future cell-based meat market will be that major brand
producers will want to engage in a similar practice.332 Not only would this be
bad for consumers, but this would be bad for free-market principles that guide
the economy.333 By preventing competitors from entering into the market
through reverse settlement payments, a cheaper, “generic” alternative will be
kept from the common consumer.334
Allowing reverse payments would also create a pseudo-monopoly.335 A
monopoly over this budding industry would stifle ingenuity and growth. In an
industry that needs more innovation to become viable, this could be a death
sentence.336
Therefore, Congress, the FDA, and the USDA need to ensure they include
language that would prevent reverse payments.337 Whether this is through an
organic act that would give the FDA and USDA supervisory power, or by
granting antitrust agencies such as the FTC the power to review the settlements,
federal authorities need to learn from how companies have circumvented HatchId. at 597.
Id.; see Ramsi A. Woodcock, Uncertainty and Reverse Payments, 84 TENN. L. REV.
99, 112–13 (2016).
331 Alyssa L. Brown, Modest Proposals for a Complex Problem: Patent Misuse and
Incremental Changes to the Hatch-Waxman Act as Solutions to the Problem of Reverse
Payment Settlements, 41 U. BALT. L. REV. 583, 590 (2012).
332 Cathy Siegner, Perdue Farms Is the Latest Company to Target Plant-Based Meat
Alternatives, FOOD DIVE (Sept. 10, 2018), https://www.fooddive.com/news/perdue-farms-isthe-latest-company-to-target-plant-based-meat-alternatives/531801/.
333 See Pay for Delay, FED. TRADE COMMISSION, https://www.ftc.gov/newsevents/media-resources/mergers-competition/pay-delay (last visited Apr. 20, 2020).
334 FTC Enters Global Settlement to Resolve Reverse-Payment Charges Against Teva,
FED. TRADE COMMISSION (Feb. 19, 2019), https://www.ftc.gov/news-events/pressreleases/2019/02/ftc-enters-global-settlement-resolve-reverse-payment-charges.
335 Joshua D. Wright, Comm’r, Fed. Trade Comm’n, Remarks at the Antitrust Masters
Course VII (Oct. 10, 2014).
336 Nicole Manuel, How Does a Monopoly Affect Business and Consumers?, CHRON
(Jan. 25, 2019), https://smallbusiness.chron.com/monopoly-affect-business-consumers70033.html; see generally Hospitals & Monopoly, OPEN MKTS.,
https://openmarketsinstitute.org/explainer/hospitals-and-monopolies/ (last visited Apr. 20,
2020) (explaining the impact of monopolies in the medical provision).
337 Tracey Toll, Pharmaceutical Reverse Payment Settlement Agreements and a
Proposal for Clarifying the Application of Antitrust Law Rule of Reason Analysis to These
Agreements, 15 HOUS. J. HEALTH L. & POL’Y 281, 284–85 (2015).
329
330
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Waxman to prevent the same kind of actions.338 Reverse settlements would be
greatly detrimental to the industry and to consumers.
B. Citizen Petitions
A second way brand companies circumvent the Hatch-Waxman Act is
through citizen petitions.339 Congress has allowed any citizen to petition an
agency;340 citizens may petition agencies to take or refrain from taking certain
administrative actions.341 Pursuant to the Administrative Procedure Act
(“APA”),342 the FDA must give the public a right to petition an agency action.343
Citizen petitions were intended to open a line of communication between the
public and the agency so that all important information concerning the agency
action is presented to the agency.344
Brand companies have been able to use these citizen petitions as a tactic to
delay agency actions, such as delaying the approval of competing generic
drugs.345 Some savvy companies will file a 505(q) citizen petition with the
FDA.346 These citizen petitions are mostly used to delay generic drug entry.347
When a citizen petition is filed, the FDA must respond within one hundred and
fifty days after the filing date.348 A brand company will typically file a petition
a few weeks before a final decision on a generic ANDA, forcing the FDA to
respond to the petition before it completes the generic drug’s approval.349 This
is an effective tactic for pushing back the approval of the generic drug’s
ANDA.350
This tactic involves what is known as an “ ‘eleventh hour’ petition because
companies would file them ‘on the eve of drug approval for the purpose of

Id.
Meagher, supra note 323, at 600.
340 Id.
341 Id.
342 Administrative Procedure Act, 5 U.S.C. §§ 551–559 (2012).
343 Id. § 553(e).
344 Scott Gottlieb, Deputy Comm’r for Med. & Sci. Affairs, Food & Drug Admin.,
Remarks Before Annual Generic Drug Forum (Apr. 7, 2006).
345 Meagher, supra note 323, at 600.
346 Id.
347 Id.
348 Id.; see also Food and Drug Administration Safety and Innovation Act of 2012
(FDASIA), Pub. L. No. 112-144, 126 Stat. 993 (codified as amended at 21 U.S.C. § 355
(2012)).
349 Meagher, supra note 323, at 600.
350 Id. at 600–01; Eric Sagonowsky, UPDATED: FDA’s New Citizen Petition Rules
Remove Speed Bumps for Generic, Biosim Approvals, FIERCEPHARMA (Nov. 9, 2016),
https://www.fiercepharma.com/pharma/fda-changes-citizen-petition-rules-to-avoid-unduegeneric-delays.
338
339
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delay.’ “351 Citizen petitions are long and complex.352 Thus, the generic drug’s
approval is often delayed for the full one hundred and fifty days.353 This tactic
effectively delays the approval of generic drugs and circumvents the amended
application process which Hatch-Waxman was designed to accelerate.354
The concern for legislation protecting cell-based meat intellectual property
and encouraging competitors to enter the market is that brand companies will
use citizen petitions to delay the approval of any other “generic” version of cellbased meat.355 Being delayed up to half a year has a major effect on profits that
generic companies could earn and profits that brand companies could retain.356
Any legislation would need to prevent or limit this stalling tactic in order to
encourage fair market competition, to protect intellectual property rights, and to
aid the consumer.357
C. Product Hopping
The final way a company may circumvent the Hatch-Waxman Act is through
“product hopping.”358 Product hopping is a strategy used when a brand
company’s patent exclusivity is about to expire, allowing for generics to seek an
ANDA to enter the market.359
The brand company will pull the brand drug from the market and quickly
Meagher, supra note 323, at 600–01.
Id. at 601.
353 Id. at 600.
354 Id.
355 Elaine Watson, Future Meat Technologies Raises $14m to Commercialize Cell
Cultured Meat: ‘We See a Path to Reality Here, It’s Not Just Something on a Power Point
Presentation,’ Says S2G Ventures, FOODNAVIGATOR-USA (Oct. 11, 2019),
https://www.foodnavigator-usa.com/Article/2019/10/11/Future-Meat-Technologies-raises14m-to-commercialize-cell-cultured-meat.
356 Sarah Zhang, How Pharma Companies Use ‘Citizen Petitions’ to Keep Drug Prices
High, THE ATLANTIC (Mar. 8, 2017), https://www.theatlantic.com/health/archive/2017/03/
pharma-citizen-petitions-drug-prices/518544/.
357 Ben Hargreaves, US FDA to Crackdown on Citizen Petition ‘Loophole’ Hindering
Generic Entry, OUTSOURCING-PHARMA.COM (Oct. 4, 2018), https://www.outsourcingpharma.com/Article/2018/10/04/US-FDA-to-crackdown-on-citizen-petition-loopholehindering-generic-entry (explaining that the FDA is working on informal rulemaking to
slow down or stop the abuse of citizen petitions).
358 New York ex rel. Schneiderman v. Actavis PLC, 787 F.3d 638, 638, 643 (2d Cir.
2015); see generally Phebe Hong, Stopping the Pharmaceutical “Product Hopping”, BILL
OF HEALTH (Oct. 11, 2019), https://blog.petrieflom.law.harvard.edu/2019/10/11/stoppingthe-pharmaceutical-product-hop/ (explaining that product hopping occurs when a
“pharmaceutical manufacturer winds down production of an old drug formulation whose
patent expiration date has passed or is approaching. The company then forces or persuades
patients to switch prescriptions to the drug’s new—and newly patented—formulation.”).
359 Meagher, supra note 323, at 605.
351
352
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substitute the drug for the company’s own generic version.360 This forces
consumers to use the company’s generic drug instead, which allows the brand
company to continue its monopoly over a specific part of market.361
Product hopping was addressed in the case of New York v. Actavis.362 In
Actavis,363 an antitrust action was commenced against Actavis.364 Namenda IR
was the Defendant’s drug designed to treat Alzheimer’s disease, but it was close
to the end of its patent exclusivity period.365 Actavis introduced a new version
of the drug called Namenda XR.366 The new version of the drug still had
exclusivity through patents.367 This would restrict other companies from
introducing other generic versions of the same drug to the market for many
years.368 To avoid competition, Actavis “decided to withdraw virtually all
Namenda IR from the market in order to force Alzheimer’s patients who depend
on Namenda IR to switch to XR before generic IR becomes available.”369 This
product hopping by Actavis restricted any generic competition on its drug, and
the cost of having the patients switch drugs “further ensure[d] that Defendants
would maintain their effective monopoly in the relevant drug market beyond the
time granted by their IR patents” and the Hatch-Waxman Act.370
The Court of Appeals for the Second Circuit held that “a scheme to coerce
patients to switch from an old product to a new one, by withdrawing from the
market with an intent to affect generic competition, violated antitrust laws.”371
Even though antitrust laws have made this tactic effectively illegal, the HatchWaxman Act does not prevent this tactic,372 and because it is not prevented by
Hatch-Waxman itself, the FDA will not catch drug companies using product
hopping.373 Companies can therefore product hop for years before they are sued
and challenged in court.374 As a result, brand companies will reap more rewards

Id.
Id.
362 Actavis PLC, 787 F.3d at 650; see Justine Amy Park, Note, Product Hopping:
Antitrust Liability and A Per Se Rule, 35 CARDOZO ARTS & ENT. L.J. 745, 745–46 (2017)
(explaining the second circuit’s holding in Actavis, which was that “product hopping,” a
scheme to force people to switch from an old product to a new one, was a violation of
antitrust laws).
363 Actavis PLC, 787 F.3d 638.
364 Id. at 642.
365 Id. at 642, 649.
366 Id. at 642.
367 Id.
368 Id.
369 Id.
370 Id. at 642–43.
371 Meagher, supra note 323, at 605; Actavis PLC, 787 F.3d at 652, 654.
372 Meagher, supra note 323, at 606; see Hatch-Waxman Act, 21 U.S.C. § 355 (2012).
373 Meagher, supra note 323, at 606.
374 Id.
360
361
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in profits and recognition than they will pay out in fines levied for antitrust
violations.375
Congress will have to include anti-product hopping language in any
legislation it enacts.376 If cell-based meat brand companies could pull their
products and introduce modified versions in order to keep exclusivity on their
products, cell lines, or growth processes, major companies could secure
monopolies over their respective areas of the market.377 If these monopolies
were to fly under the radar of federal regulators, this would keep prices higher
for consumers and inhibit critical innovation.378
The Hatch-Waxman Act has made great headway in encouraging competition
in the drug markets and cutting costs to consumers.379 Furthermore, lessons
learned about how companies have worked around the act can be used by
Congress and regulatory agencies when enacting new legislation or
promulgating new rules.380 If federal authorities want to protect secondary,
“generic” cell-based meat companies looking to compete in the budding market,
then rules and laws should be implemented to inhibit reverse payments, citizen
petitions, and product hopping. By preventing these tactics, monopolies can be
prevented, costs can be cut, and innovation can be encouraged.381
VI. ANALYSIS OF POTENTIAL PATENT PROBLEMS RELATED TO
CELL-BASED MEATS
Legislation such as the Hatch-Waxman Act solved many issues for both brand
and generic drug manufacturers by creating an extended period for companies
to maintain their patents on drugs while these drugs went through an FDA

Id.
Michael A. Carrier & Steve D. Shadowen, Product Hopping: A New Framework, 92
NOTRE DAME L. REV. 167, 168–69, 205 (2016) (proposing ways to end product hopping in
addition to antitrust laws).
377 See Babak Kusha, Future Foods - A Patent Landscape Study, KILPATRICK TOWNSEND
& STOCKTON LLP (Sept. 12, 2019), https://www.gaba-network.org/Files/Events/
Presentations/FutureFoodsPatentLandscape-BabakKusha.pdf; see generally Carrier &
Shadowen, supra note 376, at 171–72, 174, 177–78 (explaining the consequences of product
hopping in regard to drug companies, such as being able to keep exclusivity and a
monopoly).
378 Carrier & Shadowen, supra note 376, at 182–83.
379 Id. at 190.
380 Philip S. Johnson, Hatch Amendment Would Preserve Balanced Incentives for
Pharmaceutical Innovation and Drug Affordability, HEALTH AFF. BLOG (Nov. 9, 2018),
https://www.healthaffairs.org/do/10.1377/hblog20181106.217086/full/ (showing that
Congress is considering amendments to end the accidental loopholes created by the HatchWaxman Act).
381 Id.
375
376
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approval process.382 With the framework of Hatch-Waxman in mind, Congress
could create a new amendment to the FDCA that would give a time extension to
cell-based meats patents.383
As stated above, there will be many regulatory approval stages that cell-based
meat manufacturers will have to go through before they can introduce their
products into interstate commerce.384 The FDA will oversee areas such as lab
safety (including clean working areas and good manufacturing processes),385 cell
collection from animals, maintaining a clean and unadulterated cell-bank,386 and
ensuring a clean cell-growth and differentiation process for public safety.387
Even though the FDA has the infrastructure in place and the knowledge base
to handle these inspections and approvals,388 this new technology will not come
without some hiccups. FDA inspectors will need to familiarize themselves with
the terminology of the various scientific moving parts, the inspection schemes
will need to be optimized for the most efficient flow of a visit, and the scientists
who have never before been inspected by the FDA, let alone a federal
government agency, will need to adapt and change the way in which the
company stores and communicates information about its growth process.389 All
of these moving parts will create delays and increase the time it takes for labgrown meat manufacturers to get their products to grocery store shelves.390
In addition to FDA approval of the processes and quality of lab-grown meats,
manufacturers will also need approval from the Food Safety and Inspection
21 U.S.C. § 355(j) (2012).
Id.
384 See Development & Approval Process (Drugs), U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/drugs/developmentapprovalprocess/default.htm (last visited Apr. 20,
2020).
385 See generally Good Manufacturing Practice (GMP) Guidelines/Inspection Checklist,
U.S. FOOD & DRUG ADMIN., https://www.fda.gov/cosmetics/guidanceregulation/guidance
documents/ucm2005190.htm (last visited Apr. 20, 2020) (providing guidelines for FDA lab
conditions and safety protocols).
386 See generally CTR. FOR FOOD SAFETY & APPLIED NUTRITION, U.S. FOOD & DRUG
ADMIN., FDA PUBLIC MEETING TRANSCRIPT: FOODS PRODUCED USING ANIMAL CELL
CULTURE TECHNOLOGY 26–28, 43, 86 (2018), https://www.fda.gov/media/115122/download
(outlining FDA procedures for food manufactured from animal cells).
387 See generally id. at 95, 147 (outlining FDA procedures to ensure clean cell-growth
and differentiation in food manufactured from animal cells).
388 See Biotechnology Inspection Guide (11/91), U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074181.htm (last updated
Sept. 2, 2014).
389 See generally U.S. FOOD & DRUG ADMIN., INVESTIGATIONS OPERATIONS MANUAL:
CHAPTER 5 – ESTABLISHMENT INSPECTIONS (2020), https://www.fda.gov/media/76769/
download (outlining FDA procedure for conducting inspections).
390 Lauren Stine, FDA and USDA Create Framework for Cell-Cultured Meat Regulation,
But Labeling, Social License Still Uncertain, AGFUNDER (Mar. 11, 2019),
https://agfundernews.com/fda-and-usda-create-framework-for-cell-cultured-meatregulation-but-labeling-social-license-still-uncertain.html.
382
383
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Service (“FSIS”), an agency of the USDA.391 After the FDA’s inspection and
approval, there will be a transition from the FDA to the USDA for oversight at
the cell harvest stage.392 The USDA will then oversee the production and
labeling of the lab-grown meats.393 Although the USDA has the appropriate
infrastructure for handling labeling and food production oversight, this
infrastructure is currently organized and designed around living animals.394 The
USDA is not experienced in working in a pure laboratory setting.395 This will
provide a few extra hurdles to overcome when deciding what is going to be on
a label and how the harvesting of the product will occur.396 This will initially
cause delays as there will inevitably be some trial and error to optimize the
system for reporting and the collection of information.397
This transition of regulatory oversight is also something that the government
and the FDA have experience in through coordinated frameworks.398 There are
many areas in which different government agencies share responsibilities.399 For
example, the Federal Insecticide, Fungicide, and Rodenticide Act has led to an
understanding that the FDA and EPA will jointly regulate antimicrobial agents
depending upon the use.400 The most complicated uses involve antimicrobials
391 See Labeling/Label Approval, U.S. DEP’T OF AGRIC., https://www.fsis.usda.gov/wps/
portal/fsis/topics/regulatory-compliance/labeling (last visited Apr. 20, 2020).
392 Formal Agreement, supra note 18.
393 Id.
394 See id. (outlining what the USDA-FSIS will do under the agreement, with most of the
USDA-FSIS’s functions being related to “livestock”).
395 See id. (outlining the statutory responsibilities of the USDA, none of which pertain to
laboratory work); see also NATHANIEL HIGGINS ET AL., U.S. DEP’T OF AGRIC., ECONOMIC
EXPERIMENTS FOR POLICY ANALYSIS AND PROGRAM DESIGN: A GUIDE FOR AGRICULTURAL
DECISIONMAKERS 7 (2017) (noting that while the USDA will do some research experiments
in a laboratory environment, field experiments are important, especially in economic and
government policy research, since naturally occurring environments offer variables that
cannot be replicated in laboratory conditions).
396 See Formal Agreement, supra note 18 (noting that the USDA will have to coordinate
with the FDA on most decisions pertaining to labeling and harvesting the product).
397 See id. (formalizing in the agreement that the FDA and USDA will work together in
transferring regulatory oversight to the USDA).
398 Memorandum from John P. Holdren et al. on Modernizing the Regulatory System for
Biotechnology Products 2–3 (July 2, 2015).
399 See generally Memorandum of Understanding Among Dep’t of Health & Human
Servs. (Food & Drug Admin.), Dep’t of Agric. (Animal and Plant Health Inspection Serv.,
Biotechnology Regulatory Servs.), and Envtl. Prot. Agency (Office of Chem. Safety and
Pollution Prevention, Office of Pesticide Programs) (Aug. 31, 2016) (outlining EPA, FDA,
and USDA shared responsibilities for implementing the Coordinated Framework for
Regulation of Biotechnology); see also Mei Jen Hung & David H. Rosenbloomn,
Administrative Law and Culture for the U.S. Collaborative Governance State, 2009 J. DISP.
RESOL. 1, 8 (2009) (noting that for government agencies to function properly and minimize
disputes, they should consider sharing power with other agencies).
400 U.S. ENVTL. PROT. AGENCY, PESTICIDE REGISTRATION MANUAL: CHAPTER 18 - OTHER
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being used in or on food.401 These include uses such as:
[The] treatment of raw agricultural commodities in a food processing
facility [with antimicrobial agents]; [the] application of an
antimicrobial agent to process water in a food processing facility and
control a pest in the water (e.g., pulp and paperboard use, use in canesugar and beet-sugar mills); [the] production of food packaging; [the]
production of food contact articles other than food packaging; no
intended effect on the surface of the article.402
Sharing the regulation of bioengineered meats is not a new concept for the
FDA, as the agency has regulated genetically engineered meats for decades.403
An example of this is AquAdvantage Salmon, more commonly referred to as GE
Salmon.404 Even though the IP rights tied to GE organisms are still being worked
out in the courts,405 the GE Salmon model could parallel how the FDA and
USDA share the responsibility of regulating cell-based meats.406
To illustrate this point further, the executive branch’s biotechnology
coordinated framework policy has played a large part in the United States’
bioengineered product regulation.407 Initially integrated in June 1986 as the
Coordinated Framework for Regulation of Biotechnology, three agencies—the
USDA, FDA, and EPA—would share the responsibility for implementation
policies regarding biotechnology and recombinant DNA (“rDNA”) products.408
Recombinant DNA are DNA sequences that have been artificially made by
adding in a segment of DNA from one organism’s genome to another organism’s
DNA sequence.409 Recombinant DNA products can be transgenic plants,

FEDERAL OR STATE AGENCY REQUIREMENTS (2020), https://www.epa.gov/pesticideregistration/pesticide-registration-manual-chapter-18-other-federal-or-state-agency.
401 Id.
402 See generally 21 C.F.R. §§ 175–178 (2019) (providing sections of regulations
pertaining to antimicrobials used in food or food packaging); see also PESTICIDE
REGISTRATION MANUAL: CHAPTER 18 - OTHER FEDERAL OR STATE AGENCY REQUIREMENTS,
supra note 400.
403 FDA Approves 1st Genetically Engineered Product for Food, L.A. TIMES (Mar. 24,
1990), http://articles.latimes.com/1990-03-24/news/mn-681_1_genetically-engineeredproduct-for-food.
404 See Matthew Morgan, The AquAdvantage Salmon: Who Owns Escaped Genetically
Modified Animals?, 17 OCEAN & COASTAL L.J. 127, 137 (2011); see also Mark
Summerfield, Patented ‘Frankenfish’ Finally Granted FDA Approval, PATENTOLOGY (Nov.
21, 2015), https://blog.patentology.com.au/2015/11/patented-frankenfish-finallygranted.html.
405 Morgan, supra note 404, at 138.
406 Formal Agreement, supra note 18.
407 John P. Holdren et al., supra note 398, at 2.
408 Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. 23,302,
23,302–23,304 (June 26, 1986).
409 Suliman Khan et al., Role of Recombinant DNA Technology to Improve Life, 2016
INT’L J. GENOMICS (SPECIAL ISSUE) 1, 2–3.
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bacteria, or pesticides.410 These products are found widely in modern society.411
The coordinated framework resolved jurisdictional disputes among the
agencies over biotechnology products that fell within the jurisdiction of multiple
agencies, and it established the basis for much of the rDNA and biotech
regulation that exists today.412 In fact, “Since announcement of the coordinated
framework, federal regulators have cleared the way for hundreds of new
agricultural, health care, and industrial products, including dozens of plants
modified through modern biotechnology.”413 For example, a policy that came
out of the coordinated framework was that the USDA would “regulate plants
grown to produce food or feed,” and the FDA “would have jurisdiction over the
food or feed itself.”414
However, plant issues and similar issues were not addressed in the
coordinated framework.415 The coordinated framework left certain issues open,
such as how to handle transgenic plants that were modified to resist disease and
ward off insect pests because such plants technically fall under the jurisdiction
of all three agencies.416 It took nearly fourteen years for the three agencies to
finally come to a conclusion on how to regulate these cross-cutting issues with
an update in 2000,417 and the agencies still needed to amend and update the
coordinated framework again in 2017 to further resolve disputes over
regulation.418
Due to the decades-long disputes over jurisdictional issues that could not
easily be solved, there were a number of delays in biotech and rDNA products
coming to market.419 These errors and delays tied to multi-agency regulations
can be minimized if agencies clearly state and focus on their individual missions,
invite discussions at earlier stages, and promptly comply with their end of the
coordinated framework.420
In the future, a joint regulation between the FDA and the USDA over cellSee generally id. (describing products that utilize rDNA technology).
See id. (describing products that utilize rDNA technology).
412 COMM. ON GENETICALLY MODIFIED PEST-PROTECTED PLANTS, GENETICALLY
MODIFIED PEST-PROTECTED PLANTS: SCIENCE AND REGULATION 144 (2000).
413 Id.
414 Id.; Formal Agreement, supra note 18.
415 GENETICALLY MODIFIED PEST-PROTECTED PLANTS: SCIENCE AND REGULATION, supra
note 412, at 144.
416 Id. at 145.
417 Id.
418 Memorandum for Heads of Food & Drug Admin., Envtl. Prot. Agency, and Dep’t of
Agric. Regarding Modernizing the Regulatory System for Biotechnology Products to the
Exec. Office of the President (July 2, 2015).
419 GENETICALLY MODIFIED PEST-PROTECTED PLANTS: SCIENCE AND REGULATION, supra
note 412, at 178–79.
420 Id. at 178–81.
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based meats will give rise to similar jurisdictional disputes when these meat
products attempt to come to market. These disputes could result in delays during
the handoff of the approval process stage.421 For example, what constitutes a
good manufacturing process and what constitutes harvesting may become points
of contention under current FDA and USDA definitions.422 Thus, when a
company submits its process, there may be some dispute as to whose job it is to
give the approval and what exactly is approved.423
Meanwhile, the patent for the company’s manufacturing process will continue
to run while these jurisdictional issues are worked out between the FDA and the
USDA. The Hatch-Waxman Act provides a good example for Congress to
follow in authorizing the FDA to give cell-based meat producers an extension
on their patents for both processes and cell lines while the companies are
awaiting FDA approval.424
One way to address time loss on a patent is Congress could allow for time to
be added back to each of the company’s patents as an extension425 while the cellbased meat manufacturers are awaiting FDA and USDA approval of the
manufacturing process (collection stage, growth stage, and harvesting stage) and
labeling requirements.426 Time could also be reduced for a lack of action on the
part of the manufacturers so that active participation of the manufacturers can
be ensured; the FDA could do this as it already has experience in this area.427
The alternative to not having legislation that extends the length of patents on
cell-based meats is relying on the general timeframe of the current patent

Id.
Facts About the Current Good Manufacturing Practices, U.S. FOOD & DRUG ADMIN.
(June 25, 2018), https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-aboutcurrent-good-manufacturing-practices-cgmps; U.S. FOOD & DRUG ADMIN., CLASSIFICATION
OF ACTIVITIES AS HARVESTING, PACKING, HOLDING, OR MANUFACTURING/PROCESSING FOR
FARMS AND FACILITIES: GUIDANCE FOR INDUSTRY 8 (2016), https://www.fda.gov/media/
99911/download; 21 C.F.R. § 1.227 (2019) (defining harvesting as it applies to farms and
farm mixed type facilities as “activities that are traditionally performed on farms for the
purpose of removing raw agricultural commodities from the place they were grown or raised
and preparing them for use as food”).
423 See 21 C.F.R. § 110.80 (2019); Slaughter Inspection 101, U.S. DEP’T OF AGRIC.,
https://www.fsis.usda.gov/wps/portal/fsis/topics/food-safety-education/get-answers/foodsafety-fact-sheets/production-and-inspection/slaughter-inspection-101/slaughter-inspection101 (last visited Apr. 21, 2020).
424 35 U.S.C. § 156 (2012); 2750 Patent Term Extension for Delays at Other Agencies
Under 35 U.S.C. 156 [R-11.2013], U.S. PAT. & TRADEMARK OFF., https://www.uspto.gov/
web/offices/pac/mpep/s2750.html (last visited Apr. 21, 2020).
425 35 U.S.C. § 156; 2750 Patent Term Extension for Delays at Other Agencies Under 35
U.S.C. 156 [R-11.2013], supra note 424.
426 See Formal Agreement, supra note 18.
427 See generally 35 U.S.C. § 156; see also 2750 Patent Term Extension for Delays at
Other Agencies Under 35 U.S.C. 156 [R-11.2013], supra note 424.
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system.428 As of May 2017, the average pendency of a patent application is
roughly thirty-three months,429 and right now, for drugs at least, approval takes
about seven to twelve years.430 There is no indication that the approval process
for a patent tied to cell-based meats will take that long, but it is safe to assume
that it will take a year or more because of the backlog in other areas of the FDA,
such as drugs and devices.431 Therefore, cell-based meat manufacturers are
already looking at multiple years from the time of applying for a patent until
they are able to reap the rewards and benefit from their innovations.432
Even when using the fastest, most generous estimate of time, the approval of
the patents and approval from the FDA and USDA will still take a substantial
amount of time. This could amount to at least three years of earnings that these
manufacturers will have to forfeit and which investors will not be able to recover
their money from.433
However, the shortened time, especially on the design patents, will help bring
competitors into the market in a quicker way than if there were patent
extensions.434 Design patents have an average pendency anywhere from thirteen
months to nineteen months.435 If manufacturers could find a way to make design
patents sufficient to protect their works, then this would increase the supply of
cell-based meats brought to market.436 The increased supply generated from

428 Eli Lilly & Co. v. Medtronic Inc., 496 U.S. 661, 669 (1990) (addressing distortions to
the normal “patent term produced by the requirement that certain products must receive
premarket regulatory approval”).
429 Vic Lin, How Long Is the US Patent Application Process (How Much Time Does It
Take to Get a Utility Patent)?, PAT. TRADEMARK BLOG,
http://www.patenttrademarkblog.com/how-long-us-utility-patent-application-process/ (last
visited Apr. 21, 2020).
430 See generally Gail A. Van Norman, Drugs, Devices, and the FDA: Part 1 An
Overview of Approval Processes for Drugs, 1 JACC: BASIC TO TRANSLATIONAL SCI. 170,
171 (2016) (“For drugs, this process can take 10 to 15 years and cost millions of dollars.”).
431 Id.
432 See generally, Dean Best, How Can Cell-Based Food Reach Scale?, JUST-FOOD (Oct.
23, 2019), https://www.just-food.com/analysis/how-can-cell-based-food-reach-scale_
id142481.aspx (describing the risk investors take when investing in cell-based meat
products).
433 See generally id.
434 Jeffrey Kuo, Expedited Examination for Design Patent Applications in the USPTO,
POLSINELLI LLC (May 22, 2017), https://www.polsinelli.com/intelligence/blog-expeditedexamination-for-design-patent.
435 U.S. PATENT & TRADEMARK OFFICE, FY 2018 PERFORMANCE AND ACCOUNTABILITY
REPORT 56 (2018), https://www.uspto.gov/sites/default/files/documents/USPTOFY18PAR_
1.pdf.
436 See Scott J. Allan et al., Bioprocess Design Considerations for Cultured Meat
Production with a Focus on the Expansion Bioreactor, FRONTIERS IN SUSTAINABLE FOOD
SYS. (June 12, 2019), https://doi.org/10.3389/fsufs.2019.00044.
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competitors would then drive down costs.437 The biggest concern of the cellbased meat market is the cost of the meats per pound; in 2019, it was estimated
that the first meat product to market would cost about fifty dollars per pound.438
This price is still much too high to even consider making a profit at this point.439
However, in the same way generic drugs have driven down the price of brand
drugs,440 other cell-based meat manufacturers looking to scale up manufacturing
will cause the price of cell-based meats to drop.441
Even though a reduced timeframe of patents on cell-based meat products by
allowing the natural course of the patent to run would be beneficial to cost and
efficiencies, it is hard to say if three, four, or even five years is enough of a
reduction in time to see these benefits.442 Budding science still needs to attract
market investors and manufacturers to the market.443 Without these investors
and manufacturers, there would be no incentive to even consider reducing the
cost or improving the efficiency of the growing process.444
In addition, more competitors and investors would increase the
experimentation of the processes and techniques used in the growth process.445
This experimentation would help develop better manufacturing processes and
more efficient collection, growth, and harvesting processes.446 This increased
efficiency would also help drive down the cost of cell-based meat products and
increase their availability to consumers.447

437 Adam Hayes, Economics Basics: Supply and Demand, INVESTOPEDIA,
https://www.investopedia.com/university/economics/economics3.asp (last visited Apr. 21,
2020) (discussing the supply and demand curve on market economics).
438 Purdy, supra note 41.
439 See id.
440 Dena Bunis, AARP Report: Generics 18 Times Cheaper Than Brand-Name Drugs,
AARP (Apr. 8, 2019), https://www.aarp.org/politics-society/advocacy/info-2019/drug-pricereport-generics.html.
441 Clara Rodríguez Fernández, You Will Be Eating Lab-Grown Meat Soon: Here’s What
You Need to Know, LABIOTECH (Dec. 12, 2018), https://labiotech.eu/features/cultured-meatindustry/.
442 See generally Purdy, supra note 41.
443 See Frank Morris, Lab-Grown Meat Draws Big Investors—And Big Opposition, NPR
(Dec. 16, 2018), https://www.npr.org/2018/12/16/677157694/lab-grown-meat-draws-biginvestors-and-big-opposition.
444 See generally id.
445 See generally PRICEWATERHOUSECOOPERS, GROWTH REIMAGINED: PROSPECTS IN
EMERGING MARKETS DRIVE CEO CONFIDENCE 11 (2011), https://www.pwc.com/gx/en/ceosurvey/pdf/14th-annual-global-ceo-survey.pdf; Does Competition Drive Innovation?,
EDISON AWARDS, http://www.edisonawards.com/news/competition-drive-innovation/ (last
visited Apr. 22, 2020).
446 See Allan et al., supra note 436.
447 Passant Rabie, The Truth About Lab-Grown Meat, SCIENCELINE (Jan. 16, 2019),
https://scienceline.org/2019/01/the-truth-about-lab-grown-meat/.

218

THE CATHOLIC UNIVERSITY
JOURNAL OF LAW AND TECHNOLOGY

[Vol. 28.2

VII. CONCLUSION
Strong patent protections allow for innovators and manufacturers to create
and produce without the fear of being undercut or have their work stolen.448
Also, strong patent protections incentivize investments in new technologies,
thereby spurring newer, faster innovations.449 Currently, there is nothing more
innovative than the science-fiction like cell-based meats.450 As this young area
of food science is starting to bud, society needs to ensure that there are sufficient
patent protections and incentives available to allow this market to find its
niche.451
Fortunately, Congress has already worked to protect areas of new and
upcoming technology.452 Congress has experimented and has come to a
reasonable solution in the world of drug development.453 Using the current drug
regulatory sphere and the Hatch-Waxman Act as a framework, we can transpose
that on the novel and innovative area of cell-based meats.
The FDA and USDA will share regulatory oversight over the cell-based meat
products.454 This joint regulatory oversight will come with delays due to the
general approval process as well as jurisdictional questions.455 Therefore,
Congress should consider giving back time on the cell-based meat patents due
to these delays.456 This will allow for a fairer market and stronger protections
for those companies manufacturing these meat products.
Because the FDA already has the legal framework in place to handle both
public health and patent challenges,457 Congress should use the patent extensions
given to drug manufacturers in the Hatch-Waxman Act as a future legislative
guide to give patent extensions to cell-based meat manufacturers.458 In doing so,
Congress should give the FDA the responsibility of designating the time
extension as well.459 This would allow for a smoother transition for the new act
of Congress and, therefore, a more efficient process of giving the patent
extensions to manufacturers seeking to enter the cell-based meat market.

The Economic Case for a Strong Patent System, supra note 211.
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